

# DARIUS N. LAKDAWALLA

Leonard D. Schaeffer Center for Health Policy and Economics  
University of Southern California  
635 Downey Way, VPD #414-K  
Los Angeles, CA 90089-3331

(213) 538-8736  
dlakdawa@usc.edu

---

## **EDUCATION**

*University of Chicago.* Ph.D. in Economics, June 2000.

*Amherst College.* B.A., Mathematics and Philosophy, 1995. Summa Cum Laude, Phi Beta Kappa.

## **PROFESSIONAL EXPERIENCE**

- 2026-present: *University Professor of Pharmaceutical Economics and Public Policy*, University of Southern California
- 2024-present: *Chief Scientific Officer*, Leonard D. Schaeffer Institute for Public Policy and Government Service, University of Southern California
- 2012-present: *Quintiles Chair in Pharmaceutical Development and Regulatory Innovation*, University of Southern California
- 2012-present: *Full Professor*, School of Pharmacy, University of Southern California
- 2012-present: *Full Professor*, Price School of Public Policy, University of Southern California
- 2018-2024: *Director of Research*, Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California
- 2009-2013: *Director of Research*, Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California
- 2009-2012: *Associate Professor (with tenure)*, School of Policy, Planning, and Development, University of Southern California
- 2007-2009: *Director of Research*, Bing Center for Health Economics, RAND Corporation.
- 2006-2009: *Senior Economist*, RAND Corporation
- 2003-2006: *Economist*, RAND Corporation
- 2000-2003: *Associate Economist*, RAND Corporation

## **OTHER POSITIONS**

- 2025-present: *Elected Member*, National Academy of Medicine
- 2025-present: *Member*, National Academy of Medicine, Action Collaborate on Translating Emerging Science, Technology, and Innovation (ACT-ESTI)
- 2025-present: *Member*, Disability Health Research Working Group, National Institutes of Health
- 2023-present: *Member*, California Institute for Regenerative Medicine, Access and Affordability Working Group
- 2022-present: *Steering Committee*, Health Technology Assessment Panel, Research Consortium for Health Care Value Assessment
- 2019-2021: *Co-Chair*, Aspen Institute/USC Blue-Ribbon Panel on Health Technology Assessment in the U.S.
- 2019-2020: *Expert Panel Member*, “Addressing Sickle Cell Disease,” National Academy of Medicine
- 2018-2019: *Program Chair*, *Pharmaceutical Economics and Policy*, American Society of Health Economists 2019 Annual Meeting
- 2016-2025: *Associate Editor*, *Journal of Health Economics*
- 2014-2021: *Associate Editor*, *American Journal of Health Economics*

- 2013-present: *Editorial Board Member, American Journal of Managed Care: Evidence-Based Diabetes*
- 2012-present: *Editorial Board Member, American Journal of Managed Care: Evidence-Based Oncology*
- 2012-2019: *Associate Editor, Review of Economics and Statistics*
- 2010-2014: *Visiting Scholar, American Enterprise Institute*
- 2009-present: *Research Associate, National Bureau of Economic Research, Cambridge, MA Program Memberships in Health Care and Health Economics*
- 2005-present: *Editorial Board Member, BE Press Forum on Health Economics and Policy*
- 2001-2009: *Faculty Research Fellow, National Bureau of Economic Research, Cambridge, MA. Program Memberships in Health Care and Health Economics*
- 2002-2009: *Professor of Economics, Pardee RAND Graduate School of Public Policy, Santa Monica, CA*

### **PEER-REVIEWED PUBLICATIONS**

1. Basu, Anirban and **Darius N. Lakdawalla**. “A Practical Method for Estimating GRACE Utilities and Willingness to Pay Corrections.” *Value in Health. (In Press)*. DOI: <https://doi.org/10.1016/j.jval.2025.12.005>. [Editor’s Choice Article, May 2026]
2. Mulligan, Karen, Drishti Baid, Maria-Alice Manetas, **Darius N. Lakdawalla**. “Measuring the Budget Impact of Nondiscriminatory Cost-Effectiveness.” *JAMA Health Forum*. September 2025;6(9):e253076. DOI: <https://doi.org/10.1001/jamahealthforum.2025.3076>
3. Jiao, Boshen, Xinran Lu, **Darius N. Lakdawalla**, William V. Padula, Fangli Geng. “Incorporating Informal Caregiving Time Into Cost-Effectiveness Analysis for Adults Aged 50 and Older: Estimating From Health-Related Quality of Life and Functional Status.” *Value in Health*. August 2025. DOI: <https://doi.org/10.1016/j.jval.2025.07.026>
4. Chaturvedi, Ritika, Tadeja Cracner, PhuongGiang Nguyen, Hanke-Johnson, Bryan Tysinger, Dana Goldman, **Darius N. Lakdawalla**. “The Burden of Cognitive Impairment.” *Alzheimer’s & Dementia*. 2025;21(8):e70436. DOI: <https://doi.org/10.1002/alz.70436>
5. Srivastava, Gitanjali, Sophia L. Campbell, Conner R. Hill, Takara L. Stanley, Elizabeth A. Lawson, Caroline M. Apovian, Jaime P. Almandoz, Lorenzo Leggio, **Darius N. Lakdawalla**, Mohammad Dar, Carmela Socolovsky, Fatima Cody Stanford, Sarah Armstrong, and Steven K. Grinspoon. “Novel Strategies for Medical Management of Obesity: Mechanisms, Clinical Implications, and Societal Impacts: a report from the 25th annual Harvard Nutrition Obesity Symposium.” *The American Journal of Clinical Nutrition*. June 2025;122(3):866-885. DOI: <https://doi.org/10.1016/j.ajcnut.2025.06.015>
6. Axeen, Sarah, Alice J. Chen, **Darius N. Lakdawalla**, Neal Masia, Alexander Niyazov, Bhakti Arondekar, Stephen J. Freedland. “Do Trial Benefits Predict Real-World Gains in Metastatic Castration Resistant Prostate Cancer.” *JNCI Cancer Spectrum*. April 2025;9(2):pkaf018. DOI: <https://doi.org/10.1093/jncics/pkaf018>.
7. Lin, Eugene, Khristina I. Lung, Derick Rapista, Leane S. Kuo, **Darius N. Lakdawalla**, Desi Peneva, Karen Van Nuys. “Care Continuity, Nephrologists’ Dialysis Facility Preferences, and Outcomes.” *JAMA Health Forum*. 2025; 6(4):e250423. DOI: <https://doi.org/10.1001/jamahealthforum.2025.0423>.

8. Caldwell, Jillian S., Xingxing S. Cheng, Eran Bendavid, Glenn M. Chertow, **Darius N. Lakdawalla**, Eugene Lin. “Calcimimetic Prescriptions in Fee-for-Service Medicare Beneficiaries Undergoing Dialysis.” *JAMA Health Forum*. 2025; 6(4):e250452. DOI: <https://doi.org/10.1001/jamahealthforum.2025.0452>.
9. Bauer, Daniel, **Darius N. Lakdawalla**, Julian Reif. “Health Risk and the Value of Life.” *Journal of Public Economics*. 2025;245:105346. DOI: <https://doi.org/10.1016/j.jpubeco.2025.105346>.
10. Shafrin, Jason, Jaehong Kim, Joshua Cohen, Louis Garrison, Dana Goldman, Jalpa Doshi, Joshua Krieger, **Darius N. Lakdawalla**, Peter Neumann, Charles Phelps, Melanie Whittington, Richard Willke. “Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.” *Forum for Health Economics & Policy* 27(1): 29-116, November 8, 2024. DOI: <https://doi-org.libproxy1.usc.edu/10.1515/fhep-2024-0014>
11. Baid, Drishti, **Darius N. Lakdawalla**, Eric Finkelstein. “Societal Preferences for Subsidizing Treatments Targeting Patients with Advanced Illness: A Discrete Choice Experiment.” *Value in Health Regional Issues*, September 2024; 43: p.101003. DOI: <https://doi.org/10.1016/j.vhri.2024.101003>.
12. **Lakdawalla, Darius N.**, Charles E. Phelps, Hong-Hanh Nguyen. “Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous Altruism.” *Value in Health*. December 2024; 27(12):1648-1655. DOI: <https://doi.org/10.1016/j.jval.2024.06.014>.
13. Mulligan, Karen, Drishti Baid, Jason Doctor, Charles Phelps, and **Darius N. Lakdawalla**. “Risk preferences over health: Empirical estimates and implications for medical decision-making.” *Journal of Health Economics*, March 2024. DOI: <https://doi.org/10.1016/j.jhealeco.2024.102857>.
14. **Lakdawalla, Darius N.** and Jason N. Doctor. “A Principled Approach to Non-Discrimination in Cost Effectiveness.” *European Journal of Health Economics*, February 2024. DOI: <https://doi.org/10.1007/s10198-023-01659-7>.
15. **Lakdawalla, Darius N.**, Sean Tunis, Peter Neumann, Danielle Whicher, Emily Zeitler, and Barry Liden. “A Roadmap for Improving Medicare’s Application of Coverage with Evidence Development.” *Value in Health*. May 2024. DOI: <https://doi.org/10.1016/j.jval.2024.05.008>.
16. Charles, Phelps and **Darius N. Lakdawalla**. “Methods to Adjust Willingness to Pay (WTP) Measures for Severity of Illness.” *Value in Health*. July 2023; 26(7):1003-1010. DOI: <https://doi.org/10.1016/j.jval.2023.02.001>.
17. Grabowski, David C., Anuraag R. Kansal, Dana P. Goldman, and **Darius N. Lakdawalla**. “Assessment of Medical and Public Assistance Expenditures and Employment Among US Adults with Cancer Diagnoses.” *JAMA Network Open*. 2023;6(5):e2315823. DOI: <https://doi.org/10.1001/jamanetworkopen.2023.15823>.
18. Alpert, Abby, **Darius N. Lakdawalla**, and Neeraj Sood. “Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D.” *Journal of Public Economics*, May 2023; 221, 104860. DOI: <https://doi.org/10.1016/j.jpubeco.2023.104860>.
19. **Darius N. Lakdawalla** and Charles Phelps. “The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model for Measuring the Value of Gains in Health: An Exact Formulation.” *Journal of Benefit-Cost Analysis*, April 2023; 14(1):44-67. DOI: <https://doi.org/10.1017/bca.2023.6>.

20. Langbaum, Jessica B., Julie Zissimopoulos, Rhoda Au, Niranjana Bose, Chris J. Edgar, Evan Ehrenberg, Howard Fillit, Carl V. Hill, Lynne Hughes, Michael Irizarry, Sarah Kremen, **Darius N. Lakdawalla**, Nancy Lynn, Kristina Malzbender, Tetsuyuki Maruyama, Holly A. Massett, Deep Patel, Desi Peneva, Eric M. Reiman, Klaus Romero, Carol Routledge, Michael W. Weiner, Stacie Weninger, and Paul S. Aisen. "Recommendations to Address Key Recruitment Challenges of Alzheimer's Disease Clinical Trials." *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, February 2023; 19(2): 696-707. DOI: <https://doi.org/10.1002/alz.12737>.
21. Hlávka, Jakub, Bryan Tysinger, Jeffrey Yu, **Darius N. Lakdawalla**. "Access to Disease-Modifying Alzheimer's Therapies: Addressing Possible Challenges Using Innovative Payment Methods." *Value in Health*, 2022; 25(11):1828-1836. DOI: <https://doi.org/10.1016/j.jval.2022.06.003>.
22. Chen, Alice J., Jie Zhang, Abhijit Agarwal, and **Darius N. Lakdawalla**. "Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence from Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma." *Value in Health*. 2022; 25(8):1344-1351. DOI: <https://doi.org/10.1016/j.jval.2022.02.007>.
23. Yu, Jeffrey, Jakub Hlávka, Elizabeth Joe, Frances Richmond, and **Darius N. Lakdawalla**. "Impact of Non-binding FDA Guidances on Primary Endpoint Selection in Alzheimer's Disease Trials." *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 2022; 8(1). DOI: <https://doi.org/10.1002/trc2.12280>.
24. Hlávka, Jakub P., Jeffrey C. Yu, and **Darius N. Lakdawalla**. "Crosswalk between the Mini-Mental State Examination and the Telephone Interview for Cognitive Status (TICS-27/30/40)." *Journal of Alzheimer's and Dementia*, November 2022; 18(11): pp. 2036-2041. DOI: <https://doi.org/10.1002/alz.12569>.
25. Lichtenstein, Gary R., Ahva Shahabi, Seath A. Seabury, **Darius N. Lakdawalla**, Oliver Diaz Espinosa, Sarah Green, Michelle Brauer, Robert N. Baldassano. "Increased Lifetime Risk of Intestinal Complications and Extraintestinal Manifestations in Crohn's Disease and Ulcerative Colitis." *Gastroenterology & Hepatology*, 18(1), January 2022.
26. **Lakdawalla, Darius N.** and Charles Phelps. "A Guide to Extending and Implementing Generalized Risk-Adjusted Cost-Effectiveness (GRACE)." *European Journal of Health Economics* 23(3), 433-451, 2022. DOI: <https://doi.org/10.1007/S10198-021-01367-0>.
27. Reif, Julian, Hanke Heun-Johnson, Bryan Tysinger, and **Darius N. Lakdawalla**. "Measuring the COVID-19 Mortality Burden in the United States: A Microsimulation Study." *Annals of Internal Medicine*, September 2021. DOI: <https://doi.org/10.7326/M21-2239>.
28. Lin, Eugene, Khristina Ipapo Lung, Glenn Chertow, Jay Bhattacharya, **Darius N. Lakdawalla**. "Challenging Assumptions of Outcomes and Costs Comparing Peritoneal and Hemodialysis." *Value in Health*. July 30, 2021 (online). DOI: <https://doi.org/10.1016/j.jval.2021.05.017>.
29. **Lakdawalla, Darius N.** and Meng Li. "Association of Drug Rebates and Competition with Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018." *JAMA Network Open*. 2021; 4(5): pp. e219030. DOI: <https://doi.org/10.1001/jamanetworkopen.2021.9030>.
30. MacEwan, Joanna, Lauren Zhao, Katie Everson, Larry Liu, Dominik Lautsch, Fan Sun, **Darius N. Lakdawalla**. "Two Steps Forward, One Step Back: 50 Years of Societal Value From LDL-C-Lowering Therapies." *American Journal of Managed Care*. 2021; 27(4): pp. 162-168. DOI: <https://doi.org/10.37765/ajmc.2021.88618>.

31. Hlavka, Jakub, Jeffrey Yu, Dana Goldman, **Darius N. Lakdawalla**. “The Economics of Alternative Payment Models for Pharmaceuticals.” *European Journal of Health Economics*. June 2021; 22(4): pp. 559-569. DOI: <https://doi.org/10.1007/s10198-021-01274-4>.
32. **Lakdawalla, Darius N.** and Charles Phelps. “Health Technology Assessment with Diminishing Returns to Health: The Generalized Risk-Adjusted Cost Effectiveness (GRACE) Approach.” *Value in Health*. 2021; 24(2): pp. 244-249.
33. May-Slater, Suepattra, Caroline Huber, Meaghan Roach, Jason Shafrin, Wade Aubrey, **Darius N. Lakdawalla**, John Kane, Felicia Forma. “Adoption of Digital Technologies in the Practice of Behavioral Health: Qualitative Case Study of Glucose Monitoring Technology.” *Journal of Medical Internet Research*. 2021; 23(2): pp. e18119. DOI: <https://doi.org/10.2196/18119>.
34. Ermini Leaf, Duncan, Bryan Tysinger, Dana P. Goldman, and **Darius N. Lakdawalla**. “Predicting quantity and quality of life with the Future Elderly Model. *Health Economics*. November, 2021; 30(S1): pp. 52-79. DOI: <https://doi.org/10.1002/hec.4169>.
35. Helland, Eric, **Darius N. Lakdawalla**, Anup Malani, and Seth Seabury. “Unintended consequences of products liability: Evidence from the pharmaceutical market.” *Journal of Law, Economics, and Organization*. 2020; 36(3): pp. 598-632.
36. Myerson, Rebecca, Reginald Tucker-Seeley, Dana Goldman, and **Darius N. Lakdawalla**. “Does Medicare improve cancer detection and mortality outcomes?” *Journal of Policy Analysis and Management*. 2020; 39(3), pp. 577-604.
37. Sullivan, Jeffrey, Tiffany M. Shih, Emma van Eijndhoven, Yash J. Jalundhwala, **Darius N. Lakdawalla**, Cindy Zadikoff, Jennifer Benner, Thomas S. Marshall, Kavita R. Sail. “The social value of improvement in activities of daily living among the Advanced Parkinson’s disease population.” *Forum for Health Economics & Policy*. November 25, 2020; 23(2): pp. 1-23. DOI: <https://doi.org/10.1515/fhep-2019-0021>.
38. **Lakdawalla, Darius N.** and Charles Phelps. “Health Technology Assessment with Risk Aversion in Health.” *Journal of Health Economics*, July 2020, 72: 102346. DOI: <https://doi.org/10.1016/j.jhealeco.2020.102346>.
39. Lin, Eugene, Glenn Chertow, Jay Bhattacharya, and **Darius N. Lakdawalla**. “Early Delays in Insurance Coverage and Long-Term Use of Home-based Peritoneal Dialysis.” *Medical Care*, 58(7): pp. 632-642, July 2020.
40. Lichtenstein, Gary R., Ahva Shahibi, Seth A. Seabury, **Darius N. Lakdawalla**, Oliver Diaz Espinosa, Sarah Green, Michelle Brauer, Robert N. Baldassano. “Lifetime Economic Burden of Crohn’s Disease and Ulcerative Colitis by Age at Diagnosis.” *Clinical Gastroenterology and Hepatology* 2020; 18(4): pp. 889-897.
41. Baumgardner, James R., Michelle S. Brauer, Jie Zhang, Yanni Hao, Zhimei Liu, and **Darius N. Lakdawalla**. “CAR-T therapy and historical trends in effectiveness and cost-effectiveness of oncology treatments.” *Journal of Comparative Effectiveness Research*, 2020; 9(5): pp. 327-340. DOI: <https://doi.org/10.2217/ce-2019-0065>.
42. Li, Meng, **Darius N. Lakdawalla**, Dana P. Goldman. “The association between spending and outcomes for cancer patients.” *Journal of Clinical Oncology*, 2020; 38(4): pp. 323-331. DOI: <https://doi.org/10.1200/JCO.19.01451>.

43. Mattke, Soeren, Stefan Schneider, Patrick Orr, **Darius N. Lakdawalla**, and Dana Goldman. "Temporal trends in mortality after transcatheter aortic valve replacement: a systematic review and meta-regression analysis." *Structural Heart*, 2020; 4(1): pp. 16-23. DOI: 10.1080/24748706.2019.1689321.
44. Shih, Tiffany M, Kavita Sail, Yash Jalundhwala, Jeffrey Sullivan, Emma van Eijndhoven, Cindy Zadikoff, Thomas Marshall, and **Darius N. Lakdawalla**. "The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson's disease." *Journal of Medical Economics*, March 2020; 12(3): pp. 297-307. DOI: 10.1080/13696998.2019.1693383.
45. Shafrin, Jason, Alison R. Silverstein, Joanna P. MacEwan, **Darius N. Lakdawalla**, Ainslie Hatch, Felicia M. Forma. "Using Information on Patient Adherence to Antipsychotic Medication to Understand Their Adherence to Other Medications." *Pharmacy and Therapeutics*, 44(6): 350-357. June 2019.
46. MacEwan, Joanna P., Jason Doctor, Karen Mulligan, Suepattra G. May, Katherine Batt, Christopher Zacker, **Darius N. Lakdawalla**, Dana Goldman. "The Value of Progression-Free Survival in Metastatic Breast Cancer: Results from a Survey of Patients and Providers." *MDM Policy & Practice*, June 2019; 4(1). DOI: <https://doi.org/10.1177/2381468319855386>.
47. Sussell, Jesse, Jacqueline Vanderpuye-Orgle, Diana Vania, Hans-Peter Goertz, and **Darius N. Lakdawalla**. "Understanding price growth in the market for targeted oncology therapies." *American Journal of Managed Care*, 25(6): 273-277, June 2019.
48. Incerti, Devin, Jeffrey Curtis, Jason Shafrin, **Darius N. Lakdawalla**, and Jeroen P. Jansen. "A flexible open-source decision model for value assessment of biologic treatment for rheumatoid arthritis." *Pharmacoeconomics* 37(6): 829-843, June 2019.
49. Jena, Anupam Bapu, Julia Thornton Snider, Oliver Diaz Espinosa, Andy Ingram, Yuri Sanchez Gonzalez, and **Darius N. Lakdawalla**. "How Does Treating Chronic Hepatitis C Affect Individuals in Need of Organ Transplants in the United Kingdom?" *Value in Health*, Vol. 22, Issue 6, 2019, pp. 669-676.
50. Chen, Alice and **Darius N. Lakdawalla**. "Healing the Poor: The Influence of Patient Socioeconomic Status on Physician Supply Responses." *Journal of Health Economics*, 2019; 64: pp. 43-54. DOI: 10.1016/j.healeco.2019.02.001.
51. Baumgardner, James, Ahva Shahabi, Christopher Zacker, and **Darius N. Lakdawalla**. "Cost Variation and Savings Opportunities in the Oncology Care Model." *The American Journal of Managed Care*, 24(12), December 2018, pp. 618-623.
52. Jena, Anupam B., Jacquelyn W. Chou, Lara Yoon, Wade M. Aubry, Jan Berger, Wayne Burton, A. Mark Fendrick, Donna M. Fick, David Franklin, Rebecca Killion, **Darius N. Lakdawalla**, Peter J. Neumann, Kavita Patel, John Yee, Brian Sakurada, Kristina Yu-Isenberg. "Understanding and Improving Value Frameworks with Real-world Patient Outcomes." *The American Journal of Managed Care*, 24(11), November 2018, pp. 506-509.
53. Baumgardner, James R., Ahva Shahabi, Mark T. Linthicum, Christopher Zacker, and **Darius N. Lakdawalla**. "Share of Oncology Versus Nononcology Spending in Episodes Defined by the Centers for Medicare & Medicaid Services Oncology Care Model." *Journal of Oncology Practice*, 14(11): 506-509, November 2018.

54. Shafrin, Jason, Katalin Bogner, Katie Everson, Michelle Brauer, **Darius N. Lakdawalla**, and Felicia M. Forma. "Does knowledge of patient non-compliance change prescribing behavior in the real world? A claims-based analysis of patients with serious mental illness." *ClinicoEconomics and Outcomes Research*, 2018; 10: 573-585. DOI: <https://doi.org/10.2147/CEOR.S175877>.
55. **Lakdawalla, Darius N.** "The Economics of the Pharmaceutical Industry." *Journal of Economic Literature*, vol. 56, no. 2, June 2018, pp. 397-449.
56. Baumgardner, James, Ahva Shahabi, Mark Linthicum, Seanna Vine, Christopher Zacker, **Darius N. Lakdawalla**. "Greater Spending Associated with Improved Survival for Some Cancers in OCM-Defined Episodes." *Journal of Managed Care and Specialty Pharmacy*, 24(6): 504-513, June 2018.
57. MacEwan, Joanna P., Alison R. Silverstein, Jason Shafrin, **Darius N. Lakdawalla**, Ainslie Hatch, Felicia M. Forma. "Medication Adherence Patterns Among Patients with Multiple Serious Mental and Physical Illnesses." *Advances in Therapy*, 35(5), May 2018, pp. 671-685.
58. Sachs, Rachel, Nicholas Bagley and **Darius N. Lakdawalla**. "Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule." *Journal of Health Politics, Policy and Law.*, vol. 43, no. 1, 2018, pp. 5-18.
59. Phelps, Charles, **Darius N. Lakdawalla**, Anirban Basu, Michael. Drummond, Adrian Towse and Patricia Danzon. "Approaches to Aggregation and Decision Making-a Health Economics Approach: An ISPOR Special Task Force Report [5]." *Value in Health*, vol. 21, no. 2, 2018, pp. 146-154.
60. **Lakdawalla, Darius N.**, Jalpa Doshi, Louis Garrison, Charles Phelps, Anirban Basu and Patricia Danzon. "Defining Elements of Value in Health Care-a Health Economics Approach: An ISPOR Special Task Force Report [3]." *Value in Health*, vol. 21, no. 2, 2018, pp. 131-139.
61. Garrison, Louis, Peter Neumann, Richard Willke, Anirban Basu, Patricia Danzon, Jalpa Doshi, Michael Drummond, **Darius N. Lakdawalla**, Mark Pauly, Charles Phelps, Scott Ramsey, Adrian Towse and Milton Weinstein. "A Health Economics Approach to Us Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]." *Value in Health*, vol. 21, no. 2, 2018, pp. 161-165.
62. Shrestha, Anshu, Adi Eldar-Lissai, Ningqi Hou, **Darius N. Lakdawalla** and Katalin Batt. "Real-World Resource Use and Costs of Haemophilia a-Related Bleeding." *Haemophilia*, vol. 23, no. 4, 2017, pp. e267-e275.
63. Shafrin, Jason, Suepattra May, Anshu Shrestha, Charles Ruetsch, Nicole Gerlanc, Felicia Forma, Ainslie Hatch, **Darius N. Lakdawalla** and Jean-Pierre Lindenmayer. "Access to Credible Information on Schizophrenia Patients' Medication Adherence by Prescribers Can Change Their Treatment Strategies: Evidence from an Online Survey of Providers." *Patient Preference and Adherence*, vol. 11, 2017, pp. 1071-1081.
64. Shafrin, Jason, Felicia Forma, Ethan Scherer, Ainslie Hatch, Edward Vytlačil and **Darius N. Lakdawalla**. "The Cost of Adherence Mismeasurement in Serious Mental Illness: A Claims-Based Analysis." *American Journal of Managed Care*, vol. 23, no. 5, 2017, pp. e156-e163.
65. **Lakdawalla, Darius N.**, Jason Shafrin, Ningqi Hou, Desi Peneva, Seanna Vine, Jinhee Park, Jie Zhang, Ron Brookmeyer and Robert Figlin. "Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework." *Value in Health*, vol. 20, no. 7, 2017, pp. 866-875.

66. **Lakdawalla, Darius N.**, Anup Malani and Julian Reif. "The Insurance Value of Medical Innovation." *Journal of Public Economics*, vol. 145, 2017, pp. 94-102.
67. **Lakdawalla, Darius N.**, Joanna MacEwan, Robert Dubois, Kimberly Westrich, Mikel Berdud and Adrian Towse. "What Do Pharmaceuticals Really Cost in the Long Run?" *American Journal of Managed Care*, vol. 23, no. 8, 2017, pp. 488-493.
68. Jena, Anupam, Jie Zhang and **Darius N. Lakdawalla**. "The Trade-Off between Speed and Safety in Drug Approvals." *JAMA Oncology*, vol. 3, no. 11, 2017, pp. 1465-1466.
69. Bognar, Katalin, John Romley, Jay Bae, James Murray, Jacquelyn Chou and **Darius N. Lakdawalla**. "The Role of Imperfect Surrogate Endpoint Information in Drug Approval and Reimbursement Decisions." *Journal of Health Economics*, vol. 51, 2017, pp. 1-12.
70. Stevens, Warren, Desi Peneva, Jim Li, Larry Liu, Gordon Liu, Runlin Gao and **Darius N. Lakdawalla**. "Estimating the Future Burden of Cardiovascular Disease and the Value of Lipid and Blood Pressure Control Therapies in China." *BMC Health Services Research*, vol. 16, no. 175, 2016.
71. Shih, Tiffany, Craig Wakeford, Dennis Meletiche, Jesse Sussell, Adrienne Chung, Yanmei Liu, Jin Joo Shim and **Darius N. Lakdawalla**. "Reconsidering the Economic Value of Multiple Sclerosis Therapies." *American Journal of Managed Care*, vol. 22, no. 11, 2016, pp. e368-e374.
72. Shafrin, Jason, Taylor Schwartz, **Darius N. Lakdawalla** and Felicia Forma. "Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia." *Journal of Managed Care and Specialty Pharmacy*, vol. 22, no. 11, 2016, pp. 1285-1291.
73. Shafrin, Jason, Ron Brookmeyer, Desi Peneva, Jinhee Park, Jie Zhang, Robert Figlin and **Darius N. Lakdawalla**. "The Value of Surrogate Endpoints for Predicting Real-World Survival across Five Cancer Types." *Current Medical Research and Opinion*, vol. 32, no. 4, 2016, pp. 731-739.
74. Moreno, Gigi, Karen Mulligan, Caroline Huber, Mark Linthicum, David Dreyfus, Timothy Juday, Steven Marx, Yuri Gonzalez, Ron Brookmeyer and **Darius N. Lakdawalla**. "Costs and Spillover Effects of Private Insurers' Coverage of Hepatitis C Treatment." *American Journal of Managed Care*, vol. 22, no. 6 Spec No., 2016, pp. SP236-244.
75. MacEwan, Joanna, Felicia Forma, Jason Shafrin, Ainslie Hatch, **Darius N. Lakdawalla** and J. P. Lindenmayer. "Patterns of Adherence to Oral Atypical Antipsychotics among Patients Diagnosed with Schizophrenia." *Journal of Managed Care and Specialty Pharmacy*, vol. 22, no. 11, 2016, pp. 1349-1361.
76. Linthicum, Mark, Yuri Gonzalez, Karen Mulligan, Gigi Moreno, David Dreyfus, Timothy Juday, Steven Marx, **Darius N. Lakdawalla**, Brian Edlin and Ron Brookmeyer. "Value of Expanding HCV Screening and Treatment Policies in the United States." *American Journal of Managed Care*, vol. 22, no. 6 Spec No., 2016, pp. SP227-235.
77. Jena, Anupam, Warren Stevens, Yuri Gonzalez, Steven Marx, Timothy Juday, **Darius N. Lakdawalla** and Tomas Philipson. "The Wider Public Health Value of HCV Treatment Accrued by Liver Transplant Recipients." *American Journal of Managed Care*, vol. 22, no. 6 Spec No., 2016, pp. SP212-219.

78. Snider, Julia, Anupam Jena, Mark Linthicum, Refaat Hegazi, Jamie Partridge, Chris LaVallee, **Darius N. Lakdawalla** and Paul Wischmeyer. "Effect of Hospital Use of Oral Nutritional Supplementation on Length of Stay, Hospital Cost, and 30-Day Readmissions among Medicare Patients with COPD." *Chest*, vol. 147, no. 6, 2015, pp. 1477-1484.
79. Seabury, Seth, **Darius N. Lakdawalla**, J. Samantha Dougherty, Jesse Sullivan and Dana Goldman. "Medication Adherence and Measures of Health Plan Quality." *American Journal of Managed Care*, vol. 21, no. 6, 2015, pp. e379-389.
80. Romley, John, Sarah Axeen, **Darius N. Lakdawalla**, Matthew Chernen, Jay Bhattacharya and Dana Goldman. "The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization." *Health Services Research*, vol. 50, no. 3, 2015, pp. 883-896.
81. Linthicum, Mark, Julia Thornton Snider, Rhema Vaithianathan, Yanyu Wu, Chris LaVallee, **Darius N. Lakdawalla**, Jennifer Benner and Tomas Philipson. "Economic Burden of Disease-Associated Malnutrition in China." *Asia Pacific Journal of Public Health*, vol. 27, no. 4, 2015, pp. 407-417.
82. **Lakdawalla, Darius N.**, Jacquelyn Chou, Mark Linthicum, Joanna MacEwan, Jei Zhang and Dana Goldman. "Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer." *JAMA Oncology*, vol. 1, no. 2, 2015, pp. 196-202.
83. **Lakdawalla, Darius N.** and Wesley Yin. "Insurers' Negotiating Leverage and the External Effects of Medicare Part D." *Review of Economics and Statistics*, vol. 97, no. 2, 2015, pp. 314-331.
84. **Lakdawalla, Darius N.**, Jason Shafrin, Claudio Lucarelli, Sean Nicholson, Zeba Khan and Tomas Philipson. "Quality-Adjusted Cost of Care: A Meaningful Way to Measure Growth in Innovation Cost Versus the Value of Health Gains." *Health Affairs*, vol. 34, no. 4, 2015, pp. 555-561.
85. Eber, Michael., Dana Goldman, **Darius N. Lakdawalla**, Tomas Philipson, Daryl Pritchard, M. Marco Huesch, Nicholas Summers, Mark Linthicum, Jesse Sullivan and Robert Dubois. "Clinical Evidence Inputs to Comparative Effectiveness Research Could Impact the Development of Novel Treatments." *Journal of Comparative Effectiveness Research*, 2015, pp. 1-11.
86. Snider, Julia, Mark Linthicum, Yanyu Wu, Chris LaVallee, **Darius N. Lakdawalla**, Refaat Hegazi and Laura Matarese. "Economic Burden of Community-Based Disease-Associated Malnutrition in the United States." *Journal of Parenteral and Enteral Nutrition*, vol. 38, no. 2 Suppl, 2014, pp. 77S-85S0.
87. Seabury, Seth, Dana Goldman, Iftekhar Kalsekar, John Sheehan, Kimberly Laubmeier and **Darius N. Lakdawalla**. "Formulary Restrictions on Atypical Antipsychotics: Impact on Costs for Patients with Schizophrenia and Bipolar Disorder in Medicaid." *American Journal of Managed Care*, vol. 20, no. 2, 2014, pp. e52-60.
88. Mangalmurti, S., Seth Seabury, Amitabh Chandra, **Darius N. Lakdawalla**, William Oetgen and Anupam Jena. "Medical Professional Liability Risk among U.S. Cardiologists." *American Heart Journal*, vol. 167, no. 5, 2014, pp. 690-696.
89. **Lakdawalla, Darius N.**, Maria Mascarenhas, Anupam Jena, Jackie Vanderpuye-Orgle, Chris LaVallee, Mark Linthicum and Julia Snider. "Impact of Oral Nutrition Supplements on Hospital Outcomes in Pediatric Patients." *Journal of Parenteral and Enteral Nutrition*, vol. 38, no. 2 Suppl, 2014, pp. 42S-49S.

90. **Lakdawalla, Darius N.**, Anupam Jena and Jason Doctor. "Careful Use of Science to Advance the Debate on the UK Cancer Drugs Fund." *The Journal of the American Medical Association*, vol. 311, no. 1, 2014, pp. 25-26.
91. **Lakdawalla, Darius N.**, Julia Snider, Daniella Perloth, Chris LaVallee, Mark Linthicum, Tomas Philipson, Jamie Partridge and Paul Wischmeyer. "Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital?" *Forum for Health Economics and Policy*, vol. 17, no. 2, 2014, pp. 131-151.
92. Kaestner, Robert, Michael Darden and **Darius N. Lakdawalla**. "Are Investments in Disease Prevention Complements? The Case of Statins and Health Behaviors." *Journal of Health Economics*, vol. 36, 2014, pp. 151-163.
93. Gupta, Charu, Glenn Chertow, Mark Linthicum, Karen Van Nuys, Vasily Belozeroff, Darryl Quarles and **Darius N. Lakdawalla**. "Reforming Medicare's Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism." *Health Services Research.*, vol. 49, no. 6, 2014, pp. 1925-1943.
94. Goldman, Dana, Joel Fastenau, Riad Dirani, Eric Helland, Geoffrey Joyce, Ryan Conrad and **Darius N. Lakdawalla**. "Medicaid Prior Authorization Policies and Imprisonment among Patients with Schizophrenia." *American Journal of Managed Care*, vol. 20, no. 7, 2014, pp. 577-586.
95. Turakhia, Mintu, Matthew Solomon, Mehul Jhaveri, Pamela Davis, Michael Eber, Ryan Conrad, Nicholas Summers and **Darius N. Lakdawalla**. "Burden, Timing, and Relationship of Cardiovascular Hospitalization to Mortality among Medicare Beneficiaries with Newly Diagnosed Atrial Fibrillation." *American Heart Journal*, vol. 166, no. 3, 2013, pp. 573-580.
96. Solomon, Matthew, Sandeep Vijan, Felicia Forma, Ryan Conrad, Nicholas Summers and **Darius N. Lakdawalla**. "The Impact of Insulin Type on Severe Hypoglycaemia Events Requiring Inpatient and Emergency Department Care in Patients with Type 2 Diabetes." *Diabetes Research and Clinical Practice*, vol. 102, no. 3, 2013, pp. 175-182.
97. Seabury, Seth, Amitabh Chandra, **Darius N. Lakdawalla** and Anupam Jena. "On Average, Physicians Spend Nearly 11 Percent of Their 40-Year Careers with an Open, Unresolved Malpractice Claim." *Health Affairs*, vol. 32, no. 1, 2013, pp. 111-119.
98. Philipson, Tomas, Julia Snider, **Darius N. Lakdawalla**, Benoit Stryckman and Dana Goldman. "Impact of Oral Nutritional Supplementation on Hospital Outcomes." *American Journal of Managed Care*, vol. 19, no. 2, 2013, pp. 121-128.
99. **Lakdawalla, Darius N.**, Mintu Turakhia, Mehul Jhaveri, Essy Mozaffari, Pamela Davis, Lily Bradley and Matthew Solomon. "Comparative Effectiveness of Antiarrhythmic Drugs on Cardiovascular Hospitalization and Mortality in Atrial Fibrillation." *Journal of Comparative Effectiveness Research*, vol. 2, no. 3, 2013, pp. 301-312.
100. **Lakdawalla, Darius N.**, Neeraj Sood and Qian Gu. "Pharmaceutical Advertising and Medicare Part D." *Journal of Health Economics*, vol. 32, no. 6, 2013, pp. 1356-1367.
101. **Lakdawalla, Darius N.** and Neeraj Sood. "Health Insurance as a Two-Part Pricing Contract." *Journal of Public Economics*, vol. 102, 2013, pp. 1-12.
102. **Lakdawalla, Darius N.**, Michael Eber, Felicia Forma, Jesse Sullivan, Pierre-Carl Michaud, Lily Bradley and Dana Goldman. "Measuring the Value of Better Diabetes Management." *American Journal of Managed Care*, vol. 19 Spec No. 2, 2013, p. E11.

103. Goldman, Dana, Charu Gupta, Eshan Vasudeva, Kostas Trakas, Ralph Riley, **Darius N. Lakdawalla**, David Agus, Neeraj Sood, Anupam Jena and Tomas Philipson. "The Value of Diagnostic Testing in Personalized Medicine." *Forum for Health Economics and Policy*, vol. 16, no. 2, 2013, pp. 121-133.
104. Chernew, Michael, Rick McKellar, Wade Aubry, Roy Beck, Jennifer Benner, Jan Berger, A. Mark Fendrick, Felicia Forma, Dana Goldman, Anne Peters Harmel, Rebecca Killion, **Darius N. Lakdawalla**, Douglas Owens and Joe Stahl. "Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes." *American Journal of Managed Care*, vol. 19, no. 2, 2013, pp. 93-96.
105. Bognar, Katalin, Kelly Bell, **Darius N. Lakdawalla**, Anshu Shrestha, Julia Snider, N Thomas and Dana Goldman. "Clinical Outcomes Associated with Rates of Sulfonylurea Use among Physicians." *American Journal of Managed Care: Evidence-Based Diabetes*, vol. 19, 2013, pp. SP182-186.
106. Yin, Wesley, John Penrod, Ross Maclean, **Darius N. Lakdawalla** and Tomas Philipson. "Value of Survival Gains in Chronic Myeloid Leukemia." *American Journal of Managed Care*, vol. 18, no. 11 Suppl, 2012, pp. S257-264.
107. Seabury, Seth, Dana Goldman, J. Ross Maclean, John Penrod and **Darius N. Lakdawalla**. "Patients Value Metastatic Cancer Therapy More Highly Than Is Typically Shown through Traditional Estimates." *Health Affairs*, vol. 31, no. 4, 2012, pp. 691-699.
108. Seabury, Seth, Amitabh Chandra, **Darius N. Lakdawalla** and Anupam Jena. "Defense Costs of Medical Malpractice Claims." *The New England Journal of Medicine*, vol. 366, no. 14, 2012, pp. 1354-1356.
109. Philipson, Tomas, Michal Eber, **Darius N. Lakdawalla**, Mitra Corral, Rena Conti and Dana Goldman. "An Analysis of Whether Higher Health Care Spending in the United States Versus Europe Is 'Worth It' in the Case of Cancer." *Health Affairs*, vol. 31, no. 4, 2012, pp. 667-675.
110. Michaud, Pierre-Carl, Dana Goldman, **Darius N. Lakdawalla**, Yuhui Zheng and Adam Gailey. "The Value of Medical and Pharmaceutical Interventions for Reducing Obesity." *Journal of Health Economics*, vol. 31, no. 4, 2012, pp. 630-643.
111. **Lakdawalla, Darius N.** and Seth Seabury. "The Welfare Effects of Medical Malpractice Liability." *International Review of Law and Economics*, vol. 32, no. 4, 2012, pp. 356-369.
112. **Lakdawalla, Darius N.**, John Romley, Yuri Sanchez, J. Ross Maclean, John Penrod and Tomas Philipson. "How Cancer Patients Value Hope and the Implications for Cost-Effectiveness Assessments of High-Cost Cancer Therapies." *Health Affairs*, vol. 31, no. 4, 2012, pp. 676-682.
113. **Lakdawalla, Darius N.** and George Zanjani. "Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk Transfer." *Journal of Risk and Insurance*, vol. 79, no. 2, 2012, pp. 449-476.
114. **Lakdawalla, Darius N.** and Tomas Philipson. "Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets." *Journal of Law and Economics*, vol. 55, no. 1, 2012, pp. 151-187.
115. Jena, Anupam, Amitabh Chandra, **Darius N. Lakdawalla** and Seth Seabury. "Outcomes of Medical Malpractice Litigation against Us Physicians." *Archives of Internal Medicine*, vol. 172, no. 11, 2012, pp. 892-894.

116. Grabowski, David, **Darius N. Lakdawalla**, Dana Goldman, Michael Eber, Larry Liu, Tamer Abdelgawad, Andreas Kuznik, Michael Chernew and Tomas Philipson. "The Large Social Value Resulting from Use of Statins Warrants Steps to Improve Adherence and Broaden Treatment." *Health Affairs*, vol. 31, no. 10, 2012, pp. 2276-2285.
117. Darkow, Theodore, J. Ross Maclean, Geoffrey Joyce, Dana Goldman and **Darius N. Lakdawalla**. "Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia." *American Journal of Managed Care*, vol. 18, no. 11 Suppl, 2012, pp. S272-278.
118. Michaud, Pierre-Carl, Dana Goldman, **Darius N. Lakdawalla**, Adam Gailey and Yuhui Zheng. "Differences in Health between Americans and Western Europeans: Effects on Longevity and Public Finance." *Social Science and Medicine*, vol. 73, no. 2, 2011, pp. 254-263.
119. Jena, Anupam, Seth Seabury, **Darius N. Lakdawalla** and Amitabh Chandra. "Malpractice Risk According to Physician Specialty." *The New England Journal of Medicine*, vol. 365, no. 7, 2011, pp. 629-636.
120. Goldman, Dana, **Darius N. Lakdawalla**, Jesse Malkin, John Romley and Tomas Philipson. "The Benefits from Giving Makers of Conventional 'Small Molecule' Drugs Longer Exclusivity over Clinical Trial Data." *Health Affairs*, vol. 30, no. 1, 2011, pp. 84-90.
121. Faulkner, Guy, Paul Grootendorst, Van Nguyen, Tatiana Andreyeva, Kelly Arbour-Nicitopoulos, M. Christopher Auld, Sean Cash, John Cawley, Peter Donnelly, Adam Drewnowski, Laurette Dubé, Roberta Ferrence, Ian Janssen, Jeffrey LaFrance, **Darius N. Lakdawalla**, Rena Mendelsen, Lisa Powell, W. Bruce Traill and Frank Windmeijer. "Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey." *International Journal of Behavioral Nutrition and Physical Activity*, vol. 8, 2011, p. 109.
122. Sun, Eric, Anupam Jena, **Darius N. Lakdawalla**, Carolina Reyes, Tomas Philipson and Dana Goldman. "The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains." *Forum for Health Economics and Policy*, vol. 12, no. 2, 2010, pp. 1-22.
123. Philipson, Tomas, Seth Seabury, Lee Lockwood, Dana Goldman and **Darius N. Lakdawalla**. "Geographic Variation in Health Care: The Role of Private Markets." *Brookings Papers on Economic Activity*, 2010, pp. 325-361.
124. **Lakdawalla, Darius N.**, Eric Sun, Anupam Jena, Carolina Reyes, Tomas Philipson and Dana Goldman. "An Economic Evaluation of the War on Cancer." *Journal of Health Economics*, 2010, vol. 29, no. 3, pp. 333-346.
125. Jena, Anupam, Dana Goldman, Ameet Kamdar, **Darius N. Lakdawalla** and Yang Lu. "Sexually Transmitted Diseases among Users of Erectile Dysfunction Drugs: Analysis of Claims Data." *Annals of Internal Medicine*, vol. 153, no. 1, 2010, pp. 1-7.
126. Goldman, Dana, Pierre-Carl Michaud, **Darius N. Lakdawalla**, Yuhui Zheng, Adam Gailey and Igor Vaynman. "The Fiscal Consequences of Trends in Population Health." *National Tax Journal*, vol. 63, no. 2, 2010, pp. 307-330.
127. Gailey, Adam, **Darius N. Lakdawalla** and Neeraj Sood. "Patents, Innovation, and the Welfare Effects of Medicare Part D." *Advances in Health Economics and Health Services Research*, vol. 22, 2010, pp. 317-344.

128. Chen, Er, Mark Looman, Marianne Laouri, Meghan Gallagher, Karen Van Nuys, **Darius N. Lakdawalla** and Joan Fortuny. "Burden of Illness of Diabetic Macular Edema: Literature Review." *Current Medical Research and Opinion*, vol. 26, no. 7, 2010, pp. 1587-1597.
129. Stewart, Kate, David Grabowski and **Darius N. Lakdawalla**. "Annual Expenditures for Nursing Home Care: Private and Public Payer Price Growth, 1977 to 2004." *Medical Care*, vol. 47, no. 3, 2009, pp. 295-301.
130. Sood, Neeraj, Han de Vries, Italo Gutierrez, **Darius N. Lakdawalla** and Dana Goldman. "The Effect of Regulation on Pharmaceutical Revenues: Experience in Nineteen Countries." *Health Affairs*, vol. 28, no. 1, 2009, pp. w125-137.
131. **Lakdawalla, Darius N.**, Dana Goldman, Pierre-Carl Michaud, Neeraj Sood, Robert Lempert, Ze Cong, Han de Vries and Italo Gutierrez. "U.S. Pharmaceutical Policy in a Global Marketplace." *Health Affairs*, vol. 28, no. 1, 2009, pp. w138-150.
132. **Lakdawalla, Darius N.** and Neeraj Sood. "Innovation and the Welfare Effects of Public Drug Insurance." *Journal of Public Economics*, vol. 93, no. 3-4, 2009, pp. 541-548.
133. **Lakdawalla, Darius N.** and Tomas Philipson. "The Growth of Obesity and Technological Change." *Economics and Human Biology*, vol. 7, no. 3, 2009, pp. 283-293.
134. Goldman, Dana, Anupam Jena, **Darius N. Lakdawalla**, Jennifer Malin, Jesse Malkin and Eric Sun. "The Value of Specialty Oncology Drugs." *Health Services Research*, 2010, vol. 45, no. 1, pp. 115-132.
135. Bhattacharya, Jayanta, Kavita Choudhry and **Darius N. Lakdawalla**. "Chronic Disease and Trends in Severe Disability in Working Age Populations." *Medical Care*, vol. 46, no. 1, 2008, pp. 92-100.
136. **Lakdawalla, Darius N.** and Tomas Philipson. "Labor Supply and Weight." *Journal of Human Resources*, vol. 42, no. 1, 2007, pp. 85-116.
137. Berrebi, Claude and **Darius N. Lakdawalla**. "How Does Terrorism Risk Vary across Space and Time? An Analysis Based on the Israeli Experience." *Defence and Peace Economics*, vol. 18, no. 2, 2007, pp. 113-131.
138. **Lakdawalla, Darius N.**, Robert Reville and Seth Seabury. "How Does Health Insurance Affect Workers' Compensation Filing." *Economic Inquiry*, 2007, vol. 45, no. 2, pp. 286-303.
139. **Lakdawalla, Darius N.** and Tomas Philipson. "Nonprofit Production and Industry Performance." *Journal of Public Economics*, vol. 90, 2006, pp. 1681-1698
140. **Lakdawalla, Darius N.**, Neeraj Sood and Dana Goldman. "HIV Breakthroughs and Risky Sexual Behavior." *Quarterly Journal of Economics*, vol. 121, no. 3, 2006, pp. 1063-1102.
141. **Lakdawalla, Darius N.** "The Economics of Teacher Quality." *Journal of Law and Economics*, vol. 49, 2006, pp. 285-329.
142. Bhattacharya, Jay and **Darius N. Lakdawalla**. "Does Medicare Benefit the Poor?" *Journal of Public Economics*, vol. 90, no. 1-2, 2006, pp. 277-292.
143. **Lakdawalla, Darius N.** and George Zanjani. "Terrorism Insurance Policy and the Public Good." *St. John's Journal of Legal Commentary*, vol. 18, no. 2, 2005, pp. 463-469.

144. **Lakdawalla, Darius N.** and George Zanjani. "Insurance, Self-Protection, and the Economics of Terrorism." *Journal of Public Economics*, vol. 89, no. 9, 2005, pp. 1891-1905.
145. **Lakdawalla, Darius N.**, Dana Goldman and Baoping Shang. "The Health and Cost Consequences of Obesity among the Future Elderly." *Health Affairs*, vol. 24 Suppl 2, 2005, pp. W5R30-41.
146. Goldman, Dana, Baoping Shang, Jay Bhattacharya, Alan Garber, Michael Hurd, Geoffrey Joyce, **Darius N. Lakdawalla**, Constantijn Panis and Paul Shekelle. "Consequences of Health Trends and Medical Innovation for the Future Elderly." *Health Affairs*, vol. 24 Suppl 2, 2005, pp. W5R5-17.
147. Goldman, Dana and **Darius N. Lakdawalla**. "A Theory of Health Disparities and Medical Technology." *B.E. Journals in Economic Analysis and Policy: Contributions to Economic Analysis and Policy*, vol. 4, no. 1, 2005, pp. 1-30.
148. Bhattacharya, Jay and **Darius N. Lakdawalla**. "The Labor Market Value of Health Improvements." *BE Press Forum for Health Economics and Policy, Forum: Biomedical Research and the Economy*, vol. Article 2, 2005.
149. **Lakdawalla, Darius N.**, Jay Bhattacharya and Dana Goldman. "Are the Young Becoming More Disabled?" *Health Affairs*, vol. 23, no. 1, 2004, pp. 168-176.
150. **Lakdawalla, Darius N.** and Neeraj Sood. "Social Insurance and the Design of Innovation Incentives." *Economics Letters*, vol. 85, no. 1, 2004, pp. 57-61.
151. **Lakdawalla, Darius N.** and Robert Schoeni. "Is Nursing Home Demand Affected by the Decline in Age Difference between Spouses." *Demographic Research*, vol. 8, no. 10, 2003.
152. **Lakdawalla, Darius N.**, Jay Bhattacharya, Dana Goldman, Michael Hurd, Geoffrey Joyce and Constantijn Panis. "Forecasting the Nursing Home Population." *Medical Care*, vol. 41, no. 1, 2003, pp. 8-20.
153. **Lakdawalla, Darius N.** and Tomas Philipson. "The Rise in Old-Age Longevity and the Market for Long-Term Care." *American Economic Review*, vol. 92, no. 1, 2002, pp. 295-306.

#### **BOOKS**

- B1. Phelps, Charles, and **Darius N. Lakdawalla**. *Valuing Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model*. Oxford University Press, 2024.

#### **PUBLISHED CONFERENCE ABSTRACTS**

1. Mudumba, Rahul, William Padula, and **Darius N. Lakdawalla**. "Implications of Generalized Risk-Adjusted Cost-Effectiveness (GRACE) in Oncology: A Practical Implementation Guide for Equitable Decision-Making." *Medical Decision Making*, 2025, 45(7). Society for Medical Decision Making Annual Conference, 2025.
2. Mudumba, Rahul, Karen Mulligan, Jorge J. Nieva, **Darius N. Lakdawalla**. "Utility Over Multiple Indexes in Non-Small Cell Lung Cancer: Survey Estimates for Patient-Centered Generalized Risk-Adjusted Cost-Effectiveness (GRACE)." The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, 2025.

3. Mudumba, Rahul, William Padula, **Darius N. Lakdawalla**. “A Simple and Practical Guide to Implementing Generalized Risk-Adjusted Cost-Effectiveness (GRACE): A Case Study in Non-Small Cell Lung Cancer.” The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, 2025.
4. Morris, Andrew, Leonardo Ortega, Sheena Thakkar, Lisa Wilcox, Joseph Cappelleri, Devin Incerti, Monica Ines, Partha Deb, Amit Chhabra, Edward Vytlacil, Katharine Batt, **Darius N. Lakdawalla**. “Prediction of Long-Term Factor IX Durability Among Hemophilia B Patients Treated with Fidanacogene Elaparvovec Gene Therapy.” The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, 2024.
5. Incerti, Devin, **Darius N. Lakdawalla**, Patricia Dorling, Partha Deb, Edward Vytlacil, Andrew Morris, Joseph C. Cappelleri. “Generalizing the distribution and dynamics of health outcomes in clinical trials for novel treatments of rare disease to the real world.” The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe, 2022.
6. Yu, Jeffrey, Bryan Tysinger, Jakub Hlavka, **Darius N. Lakdawalla**. “Heterogeneity in the Economic Value of Early Alzheimer’s Disease-Modifying Therapies: An Analysis of Patient Subgroups.” *Value in Health*, 25(7), 2022.
7. Griffin, Susan, **Darius N. Lakdawalla**, Charles Phelps. “Dealing with Disability in Health Technology Assessment.” The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, 2022.
8. Chen, Alice, **Darius N. Lakdawalla**, and Partha Deb. “Pharmaceutical Research and Development: Incentives and Costs.” 10<sup>th</sup> Annual Conference of the American Society of Health Economics, June 2021.
9. Yu, Jeffrey, Jakub Hlavka, Bryan Tysinger, and **Darius N. Lakdawalla**. “Development of a Survey-Based Predictive Model for Clinical Dementia Rating in Alzheimer’s Disease.” *Value in Health*, 24(Suppl\_1): S242, June 2021.
10. Alpert, Abby, Alice Chen, and **Darius N. Lakdawalla**. “Can Higher Profitability Raise Pharmaceutical R&D Costs? Evidence from Medicare Part D.” 9<sup>th</sup> Annual Conference of the American Society of Health Economics, June 2020.
11. Leaf, D. Ermini, Soeren Mattke, Bryan Tysinger, **Darius N. Lakdawalla**. “Long-term Benefits of Expanded Access to Valve Replacement for Aortic Stenosis Patients.” *Value in Health* 23(Suppl\_1): S93-S94, May 2020.
12. Phelps, Charles, and **Darius N. Lakdawalla**, “Evaluation of Medical Technologies with Uncertain Benefits.” *Value in Health* 22: S774, 2019.
13. Myerson, Rebecca, Reginald Tucker-Seeley, Dana Goldman, and **Darius N. Lakdawalla**. “The Impact of Near-Universal Health Insurance Coverage on Early-Stage Cancer Detection: Evidence from Medicare.” AcademyHealth, 2019 Annual Research Meeting.
14. Lin, Eugene, Glenn Chertow, Jayanta Bhattacharya, and **Darius N. Lakdawalla**. “The impact of short-term gaps in insurance coverage on long-term peritoneal dialysis use: an instrumental variable analysis.” AcademyHealth, 2019 Annual Research Meeting.
15. MacEwan, Joanna P., Lauren Zhao, Katie Everson, Larry Liu, Sun Fang, and **Darius N. Lakdawalla**. “Evolving Clinical Benefits and Social Value of Lipid Lowering Therapies.” *Circulation: Cardiovascular Quality and Outcomes*, 12(Suppl\_1): A146-A146, April 2019.

16. Mattke, Soeren, Stefan Schneider, Patrick Orr, **Darius N. Lakdawalla**, and Dana Goldman. "Temporal Trends in 30-Day and 1-Year Mortality Rates After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Regression Analysis." *Journal of the American College of Cardiology*, 73(9S1): 1091, March 2019.
17. Jansen, Jeroen, Devin Incerti, Jason Shafrin, Andrew Frederickson, **Darius N. Lakdawalla**, and Karen Reckamp. "A Flexible Open-Source Cost-Effectiveness Model for Metastatic EGFR+ Non-Small Cell Lung Cancer." AcademyHealth, 2019 Annual Research Meeting.
18. Baumgardner, James, Katie Everson, Michelle Brauer, Jie Zhang, Yanni Hao, Jamae Liu, and **Darius N. Lakdawalla**. "CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness When Compared with Past Innovative Cancer Treatments." *Blood* 132(Suppl. 1): 322, November 21, 2018.
19. Jansen, Jeroen, Devin Incerti, Jason Shafrin, A.M. Frederickson, **Darius N. Lakdawalla**, and Karen Reckamp. "A flexible open-source cost-effectiveness model for metastatic EGFR+ non-small cell lung cancer." *Value in Health* 21: S42-S43, October 1, 2018.
20. Incerti, Devin, Jason Shafrin, **Darius N. Lakdawalla**, Lauren Zhao, Mark Linthicum, and Jeroen Jansen. "Improvement of an open-source cost-effectiveness model based on public feedback." *Value in Health* 21: S42, October 1, 2018.
21. Baldassano, Robert N., Ahva Shahabi, Seth A. Seabury, **Darius N. Lakdawalla**, Oliver Diaz, Sarah Green, Michelle Brauer, and Gary R. Lichtenstein. "Average Annual Healthcare Costs for Pediatric and Adult Patients with Crohn's Disease or Ulcerative Colitis." *Inflammatory Bowel Diseases*, 24(suppl\_1): S6, February 2018.
22. Baumgardner, James, Ahva Shahabi, Mark T. Linthicum, Seanna Vine, Christopher Zacker, and **Darius N. Lakdawalla**. "Hematologic Cancers More Costly and Have Fewer Savings Options Than Solid Tumors Under the OCM." *Blood*, 130(Supplement 1): 4713, December 2017. DOI: [https://doi.org/10.1182/blood.V130.Suppl\\_1.4713.4713](https://doi.org/10.1182/blood.V130.Suppl_1.4713.4713).
23. Lichtenstein, Gary R., Ahva Shahabi, Seth Seabury, **Darius N. Lakdawalla**, Oliver Diaz Espinosa, Sarah Green, Michelle Brauer, and Robert N. Baldassano. "Complications of Crohn's Disease and Ulcerative Colitis: Understanding the Lifetime Risks." *American Journal of Gastroenterology*, 112: S395-S396, October 2017.
24. Lichtenstein, Gary R., Ahva Shahabi, Seth Seabury, **Darius N. Lakdawalla**, Oliver Diaz Espinosa, Sarah Green, Michelle Brauer, and Robert N. Baldassano. "The Economic Burden of Crohn's Disease and Ulcerative Colitis in the United States: A Lifetime Healthcare Cost Analysis: 2017 Presidential Poster Award." *American Journal of Gastroenterology*, 112: S395-S396, October 2017.
25. Shafrin, Jason, **Darius N. Lakdawalla**, Joanna MacEwan, Alison Silverstein, Adam Hatch and Felicia Forma. "Adherence Patterns among Patients Using Oral Atypical Antipsychotics and Other Medications." *Value in Health*, vol. 20, no. 9, 2017, pp. A403.
26. Mulligan, Karen, Thanh Ton, Lara Yoon, Susan Boklage, Andreas Kuznik, Jesse Sullivan, Mina Kabiri, Mary Panaccio, Keiko Higuchi and **Darius N. Lakdawalla**. "Measuring Indirect Costs (Productivity and Caregiver Burden) in the ACC/AHA Guideline Statin Benefit Groups." *Value in Health*, vol. 20, no. 5, 2017, pp. A269-A269.

27. Sullivan, Jeffrey, Alison Sexton Ward, Beata Korytowsky, Desi Peneva, Jennifer Benner, **Darius N. Lakdawalla**, Bjorn Bolinder, Robert Figlin, and Anupam Jena. "Demonstrating Life Expectancy Gains with Immuno-Oncology (IO) Therapies." *Journal of Thoracic Oncology*, 12(1): S426.
28. MacEwan, Joanna, Jason Doctor, Suepattra May, Patrick Bonnet, Ningqi Hou, Mahlet Tebeka, and **Darius N. Lakdawalla**. "Patient Preferences for Glioblastoma Multiforme: A Discrete Choice Experiment." *Neuro-Oncology*, 18(suppl\_6): vi157, November 2016. DOI: <https://doi.org/10.1093/neuonc/nov212.651>.
29. Sullivan, Jeff, Alison Ward, Beata Korytowsky, Desi Peneva, Jennifer Benner, **Darius N. Lakdawalla**, Bjorn Bolinder, Robert Figlin, and Anupam Jena. "The Social Value of Immunotherapy in Non-Small Cell Lung Cancer." *Value in Health*, vol. 19, no. 3, 2016, pp. A167-A167.
30. **Lakdawalla, Darius N.**, Joanna MacEwan, Adrian Towse, Mikel Berdud, Kimberly Westrich and Robert Dubois. "Estimating the Lifetime Price of Pharmaceuticals: What Are the Long-Term Costs to Society?" *Value in Health*, vol. 19, no. 3, 2016, pp. A273-A273.
31. Shrestha, Anshu, Adi Eldar-Lissai, Yanyu Wu, Katherin Batt, Sangeeta Krishnan and **Darius N. Lakdawalla**. "A New Method for Counting Hemophilia-Related Bleeding Events in Claims Data." *Value in Health*, vol. 18, no. 3, 2015, pp. A2-A2.
32. Snider, Julia, Mark Linthicum, Chris LaVallee and **Darius N. Lakdawalla**. "The Impact of Oral Nutritional Supplementation in Medicare Patients with COPD." *Value in Health*, vol. 17, no. 3, 2014, pp. A179-A180.
33. Seabury, Seth, **Darius N. Lakdawalla**, Deborah Walter, John Hayes, Thomas Gustafson, Anshu Shrestha and Dana Goldman. "Medicaid Formulary Restrictions and Expenditures for Patients with Major Depressive Disorder." *Value in Health*, vol. 17, no. 3, 2014, pp. A222-A222.
34. **Lakdawalla, Darius N.**, Julia Thornton, Daniella Perloth, Chris LaVallee, Mark Linthicum, Tomas Philipson, Jamie Partridge and Paul Wischmeyer. "Effect of Oral Nutritional Supplements on Hospital Outcomes in Patients Aged 65+ with Congestive Heart Failure." *Value in Health*, vol. 17, no. 7, 2014, p. A503.
35. Stevens, Warren, Laura Henkhaus, Julia Snider and **Darius N. Lakdawalla**. "A Comparison of the Cost-Effectiveness of Low-Cost Unreimbursed Health Technologies and Commonly Reimbursed Drug Therapies." *Value in Health*, vol. 16, no. 3, 2013, pp. A259-A260.
36. Bognar, Katalin, Kelly Bell, **Darius N. Lakdawalla**, Anshu Shrestha, Julia Snider, Nina Thomas and Dana Goldman. "Health Care Costs and Clinical Outcomes Associated with Rates of Sulfonylurea Use by Physicians." *Value in Health*, vol. 16, no. 3, 2013, pp. A173-A174.
37. Pritchard, Daryl, Michael Eber, Marco Huesch, Robert Dubois and **Darius N. Lakdawalla**. "Impact of Comparative Effectiveness Research on Biomedical Innovation and Population Health." *Value in Health*, vol. 16, no. 3, 2013, pp. A266-A266.
38. **Lakdawalla, Darius N.**, Dana Goldman and Tomas Philipson. "Modeling the Health and Medical Care Spending of the Future Elderly: An Update Using the Future Elderly Model." *Value in Health*, vol. 15, no. 4, 2012, pp. A195-A196.
39. Dana Goldman, **Darius N. Lakdawalla** and Tomas Philipson. "Market Exclusivity for Drugs: The Authors Reply." *Health Affairs*, vol. 30, no. 4, 2011.

40. Zheng, Yuhui, Dana Goldman, Pierre-Carl Michaud, **Darius N. Lakdawalla**, Geoffrey Joyce, Igor Vaynman and Adam Gailey. "Projecting the Burden of Alzheimer's Disease and Evaluating the Potential Impacts of Preventing Alzheimer's Disease in the United States." *Value in Health*, vol. 13, no. 3, 2010, pp. A144-A144.
41. Sun, Eric, **Darius N. Lakdawalla**, Carolina Reyes, Dana Goldman, Tomas Philipson and Anupam Jena. "The War on Cancer: An Economic Evaluation of Recent Gains in Cancer Survival." *Value in Health*, vol. 11, no. 3, 2008, pp. A82-A82.

#### **OTHER PUBLICATIONS**

1. Ward, Alison Sexton, Elizabeth Fowler, Jeremy Shane, and **Darius N. Lakdawalla**. "High-Stakes Medicine: Rethinking Policies for the Cost and Value of Cell and Gene Therapies." USC Leonard D. Schaeffer Institute for Public Policy & Government Service. March 19, 2026.
2. Mulligan, Karen and **Darius N. Lakdawalla**. "Hidden Profits? How Accounting Conventions and Vertical Consolidation Can Obscure PBM Profitability." USC Leonard D. Schaeffer Institute for Public Policy & Government Service. January 22, 2026.
3. Chen, Alice, Jason Doctor, Louis Garrison, Jr., Dana Goldman, **Darius N. Lakdawalla**, Barry Liden, Karen Mulligan, Desi Peneva, Jason Shafrin, and Charles Phelps. "Response to the Draft Report of the Health Economics Methods Advisory (HEMA): "Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies." USC Leonard D. Schaeffer Institute for Public Policy & Government Service. October 21, 2025.
4. **Lakdawalla, Darius N.** and Dana P. Goldman. "Ensuring Most-Favored Nation Drug Pricing Doesn't Sicken Us." *STAT*. May 15, 2025.
5. **Lakdawalla, Darius N.** and Dana P. Goldman. "'Most-Favored Nation' Drug Pricing Has Three Significant Problems." *STAT*. April 14, 2025.
6. Ward, Alison Sexton, Bryan Tysinger, PhuongGiang Nguyen, **Darius N. Lakdawalla**, and Dana Goldman. "Lifetime Social Returns from Expanding Access to Anti-Obesity Medications." USC Leonard D. Schaeffer Institute for Public Policy & Government Service. March 27, 2025.
7. **Lakdawalla, Darius N.** "Medicare Drug Price Negotiations Need Something New: A Floor." *STAT*. January 22, 2025.
8. Doctor, Jason N. and **Darius N. Lakdawalla**. "How to Advance the Debate Over QALYS: A Response to Kaplan et al." *Health Affairs Forefront*. June 10, 2024.
9. Shafrin, Jason, **Darius N. Lakdawalla**, Jalpa A. Doshi, Louis P. Garrison, Jr., Anup Malani, Peter J. Neumann, Charles E. Phelps, Adrian Towse, Richard J. Willke. "A Strategy for Value-Based Drug Pricing Under the Inflation Reduction Act." *Health Affairs Forefront*. May 4, 2023.
10. Sullivan, Sean D., **Darius N. Lakdawalla**, Beth Devine, Jens Grueger, Louis P. Garrison, Jr., Josh J. Carlson, David L. Veenstra, Charles E. Phelps, Anirban Basu. "Alternatives to the QALY for Comparative Effectiveness Research." *Health Affairs Forefront*. April 21, 2023.
11. Ward, Alison Sexton, Bryan Tysinger, PhuongGiang Nguyen, Dana Goldman, **Darius N. Lakdawalla**. "Benefits of Medicare Coverage for Weight Loss Drugs." USC Leonard D. Schaeffer Center for Health Policy & Economics. April 18, 2023.

12. Goldman, D., Joseph Grogan, **Darius N. Lakdawalla**, Barry Liden, Jason Shafrin, Kyi-Sin Than, Erin Trish. “Mitigating the Inflation Reduction Act’s Adverse Impacts on the Prescription Drug Market.” USC Leonard D. Schaeffer Center for Health Policy & Economics, April 13, 2023.
13. **Lakdawalla, Darius N.** and Julian Reif. “The hidden cost of Covid-19: years of life lost among the young.” *STAT+*. October 14, 2021.
14. Mulligan, Karen and **Darius N. Lakdawalla**. “Federal government should advise on drug negotiations, not run them.” *Modern Healthcare*. September 23, 2021.
15. Ward, Alison S., Karen Van Nuys, and **Darius N. Lakdawalla**. “Reducing Racial Disparities in Early Cancer Diagnosis with Blood-Based Tests.” USC Leonard D. Schaeffer Center for Health Policy & Economics. July 2021.
16. Goldman, Dana and **Darius N. Lakdawalla**. “FDA’s approval of aducanumab paves the way for ‘more momentous’ Alzheimer’s breakthroughs.” *STAT+*. June 7, 2021.
17. Ward, Alison S., Karen Van Nuys, **Darius N. Lakdawalla**. “Impacts of First-in-Class Drug Approvals on Future In-Class Innovation.” USC Leonard D. Schaeffer Center for Health Policy & Economics. May 2021.
18. **Lakdawalla, Darius N.**, Dana Goldman, Karen Van Nuys, Dan Mendelson. “Reassessing the Value of Minimally Invasive Technologies in the Era of COVID-19.” USC Schaeffer Center for Health Policy and Economics. March 17, 2021.
19. **Lakdawalla, Darius N.**, Peter Neumann, Gail Wilensky. “Create a U.S. Institute of Health Technology Assessment to Preserve Innovation and Control Costs.” *STAT+*. March 2021.
20. **Lakdawalla, Darius N.**, Peter J. Neumann, Gail R. Wilensky, Alan Balch, Jalpa A. Doshi, Louis P. Garrison, Margaret A. Hamburg, Joel W. Hay, Zeba M. Khan, Finn Bertum Kristensen, Samuel R. Nussbaum, Daniel A. Ollendorf, William V. Padula, Charles E. Phelps, Dana Gelb Safran, Mark J. Sculpher, Sean R. Tunis, Dana P. Goldman, Ruth Katz, Karen Mulligan, Desi Peneva. “Health Technology Assessment in the U.S.: A Vision for the Future.” USC Schaeffer Center for Health Policy and Economics. February 2021.
21. **Lakdawalla, Darius N.**, Erin Trish. “Why pooled testing could be a breakthrough in the fight against COVID-19.” *The Conversation*. July 20, 2020.
22. **Lakdawalla, Darius N.**, Emmet Keeler, Dana Goldman, Erin Trish. “Getting Americans Back to Work (and School) with Pooled Testing.” USC Schaeffer Center for Health Policy and Economics. May 2020.
23. **Lakdawalla, Darius N.** and Charles Phelps. “Evaluation of Medical Technologies with Uncertain Benefits.” *American Journal of Managed Care: Clinical Brief*. February 2020.
24. Mulligan, Karen., **Darius N. Lakdawalla**, Peter J. Neumann, Gail R. Wilensky, Dana P. Goldman, Ruth J. Katz, Jakub Hlavka, Desi Peneva, Martha Ryan. “Health Technology Assessment for the U.S. Healthcare System. USC Schaeffer Center for Health Policy and Economics and The Aspen Institute. February 2020.
25. Goldman, Dana and **Darius N. Lakdawalla**. “Health Care’s Killer App: Life Insurance.” *Wall Street Journal* op-ed, March 20, 2019.

26. Mattke, Soren, **Darius N. Lakdawalla**, and Dana Goldman. “The Long Road to Value-Based Payment: The Case of Transcatheter Aortic Valve Replacement.” *Health Affairs Blog*, July 26, 2018.
27. Goldman, Dana, and **Darius N. Lakdawalla**. “The Global Burden of Medical Innovation.” USC Leonard D. Schaeffer Center for Health Policy and Economics, January 2018.
28. Conti, Rena, and **Darius N. Lakdawalla**. “Putting More into Biopharmaceutical Value Assessments.” *Health Affairs Blog*, January 3, 2018.
29. Chou, Jacquelyn, Glenn Chertow, **Darius N. Lakdawalla**, Alon Yehoshua, and Vasily Belozeroff. “Bundled Payments: Balancing Incentives, Quality, and Affordability.” *Health Affairs Blog*, December 20, 2017.
30. Goldman, Dana and **Darius N. Lakdawalla**. “Take Me Out to the Pill Game.” *Wall Street Journal* op-ed, June 19, 2017.
31. **Lakdawalla, Darius N.**, Anup Malani, and Jay Bhattacharya. “Why America Needs a Do-Over on Medicaid Reform.” *The Conversation*, May 11, 2017.
32. Balch, Alan, and **Darius N. Lakdawalla**. “The Case for Patient-Centered Assessment of Value.” *Health Affairs Blog*, May 8, 2017.
33. Sachs, Rachel, Nicholas Bagley, and **Darius N. Lakdawalla**. “Value-Based Pricing for Pharmaceuticals in the Trump Administration.” *Health Affairs Blog*, April 27, 2017.
34. Jena, Anupam, and **Darius N. Lakdawalla**. “Value Frameworks for Rare Diseases: Should They Be Different?” *Health Affairs Blog*, April 12, 2017.
35. **Lakdawalla, Darius N.**, and Anup Malani. “How Republicans and Democrats Can Both Keep Their Promises on Health Care.” *The Conversation*, March 2, 2017.
36. **Lakdawalla, Darius N.**, and Anup Malani. “Do You Know What the Affordable Care Act Does? Here’s a Primer to Help.” *The Conversation*, February 27, 2017.
37. **Lakdawalla, Darius N.**, Mark Linthicum and Jackie Vanderpuye-Orgle. "Does Patient Cost Sharing for HCV Drugs Make Sense?" *American Journal of Managed Care*, vol. 22, no. 6 Spec No., 2016, pp. SP188-190.
38. **Lakdawalla, Darius N.**, and Dana Goldman. “Why Academics Consulting with Industry on Health Care May Be an Idea Whose Time Has Come.” *The Conversation*, December 21, 2016.
39. Goldman, Dana, and **Darius N. Lakdawalla**. “Election Verdict: Pharma Needs a New Prescription.” *StatNews*, November 10, 2016.
40. Philipson, Tomas, and **Darius N. Lakdawalla**. “All or Nothing? Rethinking the FDA Approval Framework.” *Forbes*, November 4, 2016.
41. **Lakdawalla, Darius N.**, and Peter Neumann. “Budget Criteria and Value Assessments: A Case of Apples and Oranges?” *Health Affairs Blog*, September 22, 2016.
42. **Lakdawalla, Darius N.**, and Julian Reif. “Health, body weight, and obesity.” *The Oxford Handbook of Economics and Human Biology*, 2016.

43. Goldman, Dana P., **Darius N. Lakdawalla**, James R. Baumgardner, and Mark T. Linthicum. "Are Biopharmaceutical Budget Caps Good Public Policy?" *The Economists' Voice* 13(1):27-42, 2016.
44. **Lakdawalla, Darius N.**, Anup Malani, and Julian Reif. "The Complex Relationship Between Healthcare Reform and Innovation." *The Future of Healthcare Reform in the United States*, Anup Malani and Michael H. Schill, eds., University of Chicago Press, 2015.
45. **Lakdawalla, Darius N.** (2015, September 23). "Drug Price Controls End Up Costing Patients Their Health." *New York Times*, Retrieved from <http://www.nytimes.com/roomfordebate/2015/09/23/should-the-government-impose-drug-price-controls/drug-price-controls-end-up-costing-patients-their-health>
46. Goldman, Dana, and **Darius N. Lakdawalla**. "Moving Beyond Price-Per-Dose in the Pharmaceutical Industry." Web blog post. *Health Affairs Blog*. Health Affairs, 30 September 2015. Web.
47. Goldman, Dana, **Darius N. Lakdawalla**, and Lee Newcomer. "It's Time for Value-Based Payment in Oncology." Web blog post. *Health Affairs Blog*. Health Affairs, 28 April 2015. Web.
48. Goldman, Dana, **Darius N. Lakdawalla**, and Tomas Philipson. "Morality versus Survival in International Comparisons of Cancer Care." Web blog post. *Health Affairs Blog*. Health Affairs, 20 March 2015. Web.
49. Dayoub, Elias, Anupam Jena, and **Darius N. Lakdawalla**. "The End of the Blockbuster? Implications for Pricing of New Drugs." Web blog post. *Health Affairs Blog*. Health Affairs, 16 June 2014. Web.
50. Goldman, Dana, Adam Leive and **Darius N. Lakdawalla**. "Want More Value from Prescription Drugs? We Need to Let Prices Rise and Fall?" *The Economists' Voice*, vol. 10, no. 1, 2013, pp. 39-43.
51. **Lakdawalla, Darius N.**, Jay Bhattacharya, Amitabh Chandra, Michael Chernew, Dana Goldman, Anupam Jena, Anup Malani, and Tomas Philipson. "Best of Both Worlds: Uniting Universal Coverage and Personal Choice in Health Care." *American Enterprise Institute*, August 2013.
52. Seabury, Seth, **Darius N. Lakdawalla** and Dana Goldman. "Patients' Willingness to Pay: The Authors Reply." *Health Affairs*, vol. 31, no. 8, 2012, doi:10.1377/hlthaff.2012.0713.
53. Marco Huesch and **Darius N. Lakdawalla**. "Freedom to Innovate: The Perils of Centralized Medical Research." *Archives of Internal Medicine*, vol. 172, no. 21, 2012, pp. 1692-1693; author reply 1693.
54. Goldman, Dana, Steven Schwartz, **Darius N. Lakdawalla**, Tomas Philipson, and Anupam Jena. "Harnessing the Promise of Comparative Effectiveness Research." Web blog post. *Health Affairs Blog*. Health Affairs, 12 September 2012. Web.
55. Eber, Michael, Dana Goldman, **Darius N. Lakdawalla**, and Tomas Philipson. "When Epidemiology Goes Astray: Valuing Cancer Care in the Unites States and Europe." Web blog post. *Health Affairs Blog*. Health Affairs, 14 May 2012. Web.
56. Chernew, Michael, **Darius N. Lakdawalla**, and Dana Goldman. "Saving Medicare Dollars: Moving from the SGR to Bundled Payments." Web blog post. *Health Affairs Blog*. Health Affairs, 24 February 2012. Web.

57. Goldman, Dana, and **Darius N. Lakdawalla**. "Intellectual Property." *Handbook of Health Economics*, Chapter 13, New York: Elsevier Science, 2012.
58. **Lakdawalla, Darius N.**, and Neeraj Sood. "Incentives to Innovate." *Oxford Handbook of the Economics of the BioPharmaceutical Industry*. New York: Oxford, 2012.
59. Seabury, Seth, Amitabh Chandra, **Darius N. Lakdawalla** and Anupam Jena. "Defense Costs of Medical Malpractice Claims." *The New England Journal of Medicine*. 2012.
60. Huckfeldt, Peter, **Darius N. Lakdawalla**, and Tomas J. Philipson. "Economics of Obesity." *Elgar Companion to Health Economics, 2<sup>nd</sup> Edition*, Chapter 7 (2), 2012.
61. Goldman, Dana, **Darius N. Lakdawalla**, and Yuhui Zheng. "Food Prices and the Dynamics of Body Weight." *Economic Aspects of Obesity*. Chicago: University of Chicago Press, 2011.
62. Goldman, Dana, **Darius N. Lakdawalla**, Tomas Philipson and Wesley Yin. "Valuing Health Technologies at NICE: Recommendations for Improved Incorporation of Treatment Value in HTA." *Health Economics*, vol. 19, no. 10, 2010, pp. 1109-1116.
63. Gailey, Adam, **Darius N. Lakdawalla**, and Neeraj Sood. "Patents, Innovation, and the Welfare Effects of Medicare Part D." *Advances in Health Economics and Health Services Research*. New York: Elsevier, 2010.
64. Goldman, Dana and **Darius N. Lakdawalla**. "Can the ACA Improve Population Health?" *The Economists' Voice* 7 (5): Article 4. December 2010.
65. Goldman, Dana, **Darius N. Lakdawalla**, Tomas Philipson, and Wesley Yin. "Valuing Health Technologies at NICE: Recommendations for Improved Incorporation of Treatment Value in HTA." *Health Economics* 19 (10): 1109-1116. October 2010.
66. **Lakdawalla, Darius N.** and Tomas Philipson. "Economics of Obesity." *Elgar Companion to Health Economics*. Cambridge: Edward Elgar, 2006.
67. **Lakdawalla, Darius N.**, Tomas Philipson and Jay Bhattacharya. "Welfare-Enhancing Technological Change and the Growth of Obesity." *American Economic Review: AEA Papers and Proceedings*, vol. 95, no. 2, 2005, pp. 253-257.
68. Bhattacharya, Jay, David Cutler, Dana Goldman, Michael Hurd, Geoffrey Joyce, **Darius N. Lakdawalla**, Constantijn Panis and Baoping Shang. "Disability Forecasts and Future Medicare Costs." *Frontiers in Health Policy Research*, edited by David Cutler and Alan M. Garber, vol. 7, MIT Press, 2004.
69. **Lakdawalla, Darius N.**, and George Zanjani. "Terrorism Insurance Policy and the Public Good." *St. John's Journal of Legal Commentary* 18(2): 463-469, Spring 2004.
70. Bhattacharya, Jay, David Cutler, Dana Goldman, Michael Hurd, Geoffrey Joyce, **Darius N. Lakdawalla**, Constantijn Panis, and Baoping Shang. "Disability Forecasts and Future Medicare Costs." *Forum for Health Economics and Policy*, 7(1), Jan 2004.
71. **Lakdawalla, Darius N.**, Jay Bhattacharya and Dana Goldman. "A Response to the Points by Manton and Williamson." *Medical Care*, vol. 41, no. 1, 2003, pp. 28-31.
72. **Lakdawalla, Darius N.** "Quantity over Quality." *Education Next*, 2002, pp. 66-72.

73. Goldman, Dana and **Darius N. Lakdawalla**. "A New Method for Determining Patient Payments for Outpatient Drugs." *American Journal of Managed Care*, vol. 8, no. 2, 2002, pp. 125, 128, 130.
74. Goldman, Dana, and **Darius N. Lakdawalla**. "Comment on 'A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost.'" *American Journal of Managed Care* 8(2): 125-8, February 2002.
75. **Lakdawalla, Darius N.**, and Tomas Philipson. "Public Financing and the Market for Long-Term Care." *Frontiers in Health Policy Research 4*, edited by Alan Garber, NBER. Chicago: University of Chicago Press, 2001.
76. Philipson, Tomas, and **Darius N. Lakdawalla**. "Medical Care Output and Productivity in the Nonprofit Sector." In *Medical Care Output and Productivity*, edited by David Cutler and Ernst Berndt. NBER Studies in Income and Wealth, Volume 62. Chicago: University of Chicago Press, 2001.

### GRANTS

1. *Co-Principal Investigator, National Institute on Aging, R01 Grant Award*. "Ensuring Access to Novel Alzheimer's and Dementia Treatments: Evaluating Innovative Payment Approaches." (Co-Principal Investigator: Dana Goldman)
2. *Co-Project Leader, Covered CA, Grant Submission*. "Evaluating Performance in the California Healthcare Exchanges." \$75,000 total. (Co-Project Lead: Wesley Yin)
3. *Co-Principal Investigator, National Institute on Aging, R01 Grant Submission*. "Physician Perceptions of Medical Malpractice." (Co-Principal Investigator: Seth Seabury)
4. *Project Lead, National Institute of Health, P01 Grant Award*. March 2012-February 2016. "The Behavioral Effects of Prescription Drug Use." 4 years, \$1,888,468 total. (Co-Project Lead: Robert Kaestner)
5. *Principal Investigator, National Institute on Aging, R01 Grant Award*. May 2009-May 2013. "Medical Malpractice, Health Care Costs, and Technology Adoption." 4 years, \$1,300,000 total. (Co-Principal Investigator: Seth Seabury.)
6. *Co-Project Leader, National Institute on Aging, P01 Grant Award*. July 2005-June 2010. "Causes and Consequences of Obesity Among Older Americans." (Principal Investigator: Michael Hurd. Project Leader: Dana Goldman)
7. *Co-Principal Investigator, National Institute on Aging, R01 Grant Award*. July 2006-June 2010. "Obesity Among Older Americans." (Principal Investigator: Dana Goldman)
8. *Principal Investigator, National Institute on Aging, R01 Grant Award*. August 2004-August 2007. "Whom Does Medicare Benefit?" 3 years, \$696,000 total. (Co-Principal Investigators: Jay Bhattacharya and Michael Schoenbaum)
9. *Principal Investigator, National Institute on Aging, R03 Grant Award*. June 2005-May 2007. "Medical Malpractice: Implications for Cost and Technology." 2 years, \$174,000 total. (Co-Principal Investigator: Seth Seabury.)
10. *Co-Principal Investigator, National Institute of Child Health and Human Development, R03 Grant Award*. September 2004-August 2006. "Childlessness: Choice or Chance?" 2 years, \$174,000 total. (Principal Investigator: David Loughran. Co-Principal Investigator: Julie Zissimopoulos.)

11. *Principal Investigator, National Institute of Occupational Safety and Health, R03 Grant Award.* August 2002-August 2004. “Unclaimed Injuries and Workers’ Compensation Adequacy.” 2-year, \$172,000 total. (Co-Principal Investigator: Robert Reville.)
12. *Principal Investigator, National Institute on Aging, R03 Grant Award.* September 2001-September 2002. “The Redistributive Effects of Medicare.” 1 year, \$86,000 total. (Co-Principal Investigators: Jay Bhattacharya and Michael Schoenbaum)
13. *Principal Investigator, National Institute on Aging, R03 Grant Award.* May 2001-May 2002. “Age Difference of Spouses and Long-Term Care.” 1 year, \$86,000 total. (Co-Principal Investigator: Robert Schoeni)

#### **AWARDS**

- *2025 Value in Health Regional Issues Paper of the Year Award* – awarded to recognize best paper published in the *Value in Health Regional Issues* journal each year.
- *2021 ISPOR HEOR Excellence – Methodological Award* – awarded to recognize outstanding research in the field of health economics and outcomes research (HEOR) methodology.
- *2020 PhRMA Foundation Value Assessment Challenge Award, First Place* – awards designed to encourage innovative approaches to defining and measuring value in health care.
- *2019 PhRMA Foundation Value Assessment Challenge Award, Third Place* – awards designed to encourage innovative approaches to defining and measuring value in health care.
- *2016 JMCP Award for Excellence* – awarded annually to recognize an article that represents the best scholarly work in managed care pharmacy, for “Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia.”
- *2009 Eugene Garfield Economic Impact of Medical and Health Research Award* – awarded annually to an outstanding paper demonstrating how medical and health research impacts the economy, for “US Pharmaceutical Policy in a Global Marketplace.”
- *2007 Edwin E. and Mary T. Huddleson Award for Outstanding Teaching*, Pardee RAND Graduate School of Public Policy.
- 2003 Milken Institute Award for Distinguished Economic Research — awarded for “Technological Change and the Growth of Obesity.”
- *T.W. Schultz Dissertation Fellowship*, University of Chicago, September 1999-June 2000.
- *Nonprofits Fellowship*, National Bureau of Economic Research, September 1998-1999.
- *Century Scholarship*, University of Chicago, September 1995-June 1999.

#### **GOVERNMENT TESTIMONY**

- *United States House of Representatives, Committee on Oversight and Government Reform. Joint Subcommittee Hearing.* “Lowering the Cost of Health Care: Technology’s Role in Driving Affordability.” December 10, 2025.
- *United States Senate, Committee on Health, Education, Labor, and Pensions. Full Committee Hearing.* “Why Does the United States Pay, by Far, the Highest Prices in the World for Prescription Drugs.” February 8, 2024.
- *United States House of Representatives, Committee on Ways and Means, Health Subcommittee.* “Hearing on Examining Policies that Inhibit Innovation and Patient Access.” May 10, 2023.
- *California Assembly Select Committee on Biotechnology.* “Informational Hearing.” February 12, 2014.

#### **TEACHING EXPERIENCE**

- *Risk Analysis (PPD 587)*, University of Southern California School of Policy, Planning and

Development and Viterbi School of Engineering. Graduate-level course in the Master's in Public Policy and Public Policy Doctoral sequences.

- *Introduction to/Fundamentals of Health Policy and Management (PPD 325)*, University of Southern California School of Policy, Planning and Development. Graduate-level course in the Master's in Public Policy and Public Policy Doctoral sequences.
- *Health Economics II (PMEP 544)*, University of Southern California School of Policy, Planning, and Development. Graduate-level course in the Public Policy Doctoral sequences.
- *Health Policy (PPD 415)*, University of Southern California School of Policy, Planning, and Development. Undergraduate elective in the health policy sequence.
- *Advanced Microeconomics*, Pardee RAND Graduate School of Public Policy, 2003-2009. Co-taught one quarter in Ph.D. microeconomics sequence.
- *Microeconomics Curriculum*, Pardee RAND Graduate School of Public Policy, Fall 2002. Served on 4-person committee that guided the redesign and implementation of a new microeconomics curriculum for the Ph.D. program in Public Policy.

#### **SELECTED REFEREEING ACTIVITY**

- *American Economic Journals*
- *American Economic Review*
- *American Journal of Health Economics*
- *B.E. Journals of Economic Analysis and Policy*
- *Blood Journal*
- *Demography*
- *Econometrica*
- *Economic Inquiry*
- *Economic Journal*
- *Economics and Human Biology*
- *Education Finance and Policy*
- *European Economic Review*
- *Education Next*
- *Forum for Health Economics and Policy*
- *Geneva Papers on Risk and Insurance*
- *Health Affairs*
- *Health Economics*
- *Health Services Research*
- *International Economic Review*
- *International Journal of Health Care Finance and Economics*
- *JAMA Oncology*
- *Journal of the American Medical Association*
- *Journal of Applied Econometrics*
- *Journal of Development Economics*
- *Journal of Economic Literature*
- *Journal of Empirical Legal Studies*
- *Journal of the European Economic Association*
- *Journal of Gerontology: Social Sciences*
- *Journal of Health Economics*
- *Journal of Human Capital*
- *Journal of Human Resources*
- *Journal of Labor Economics*
- *Journal of Policy Analysis and Management*

- *Journal of Political Economy*
- *Journal of Public Economics*
- *Journal of Regional Science*
- *Journal of Risk and Insurance*
- *The Milbank Quarterly*
- *National Tax Journal*
- *New England Journal of Medicine*
- *PharmacoEconomics*
- *Quarterly Journal of Economics*
- *Review of Economic Studies*
- *Review of Economics of the Household*
- *Review of Economics and Statistics*
- *Social Science and Medicine*
- *Social Science Research*
- *Cambridge University Press*
- National Institutes of Health
- National Science Foundation
- US Department of Agriculture Economic Research Service

#### **PROFESSIONAL AFFILIATIONS**

- American Economic Association
- International Society for Pharmacoeconomics and Outcomes Research
- American Society for Health Economists

#### **SELECTED POPULAR PRESS MENTIONS**

- Jarvis, Lisa. “The Push for Lower US Drug Prices Uses Bad Logic.” *Bloomberg* (online), January 16, 2026.
- Walker, Leslie. “Will Trump’s Prescription Drug Deals Really Lower Prices?” *Tradeoffs* (online), October 23, 2025.
- Editorial Board. “Those annoying pharmaceutical ads have real value.” *The Washington Post*, July 28, 2025.
- Ackerman, Daniel. “How excess deaths in the COVID-19 pandemic impacted Social Security.” *Marketplace* (podcast), February 19, 2025.
- Osman, Maaisha. “Expert: Implementing CED Differently Could Help Boost Innovation.” *Inside Health Policy* (online), October 22, 2024.
- Constantino, Annika Kim. “Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say.” *CNBC Health and Science* (online), April 13, 2023.
- American Health Law Association. “COVID-19 Implications for Pharmaceutical Litigation.” *Health Law Weekly* (podcast), July 17, 2020.
- **Lakdawalla, Darius N.** and Erin Trish. “Group testing for coronavirus – called pooled testing – could be the fastest and cheapest way to increase screening nationwide.” *The Conversation* (online), July 20, 2020. DOI: 10.64628/AAI.nxwumxanm
- Perrone, Matthew, “‘Pooled testing’ for COVID-19 holds promise, pitfalls.” *Associated Press* (online), June 30, 2020.
- Azvolinsky, Anna. “Despite Generic Imatinib, Cost of Treating CML Remains High.” *Cancer Today* (online). February 24, 2020.
- Wapner, Jessica, “Medication keeps getting more expensive – and big pharma won’t explain why.” *Newsweek* (online), April 24, 2018.

- Callery, Taylor, “How to reboot the FDA.” *Politico* (online), December 13, 2017.
- Mason, Melanie, “What would California’s proposed single-payer healthcare system mean for me?” *Los Angeles Times* (online), June 1, 2017.
- Finkl, Ed. “A prescription to help cure high drug costs?” *Medical Economics* (online), May 25, 2017.
- Gregory, Sean and Alexandra Sifferlin, “President Trump Vow to Solve the Opioid Crisis. He Needs to Fix this Problem First.” *Time* (online), February 24, 2017.
- Sharon, Jason and Mark Linthicum, “Advancing Value in Healthcare.” *Genetic Engineering & Biotechnology News* (online), December 12, 2016.
- Hiltzik, Michael, “Will the Trump presidency mean the end of FDA drug regulation?” *Los Angeles Times* (online), November 16, 2016.
- Chang, Alicia, “Prop 61: Big Pharma scores expensive win on California ballot measure.” *The Mercury News* (online), November 10, 2016.
- Associated Press, “Prop 61: Big Pharma scores over drug prices.” *KSBW* (online), November 9, 2016.
- Swaminathan, Nikhil, “Precision medicine may be health care’s next big thing, but we don’t yet know how to evaluate precision drugs.” *Quartz Media* (online), November 1, 2016.
- Pearson, Steven, “Value: Can we afford to think long-term while ignoring budget impact?” *Health Affairs Blog* (online), September 22, 2016.
- Stanton, Dan et al. “Quality for burgeoning US biosimilars market, says BIO panel.” [www.biopharma-reporter.com](http://www.biopharma-reporter.com), June 17, 2016.
- Perrone, Matthew, “Apps help people find best drug prices.” *The Columbian* (online). June 6, 2016.
- Perrone, Matthew, “Why not shop for lower prescription drugs prices?” *The Salt Lake Tribune* (online), June 2, 2016.
- Perrone, Matthew, “Why aren’t you shopping for lower prescription drug prices?” [www.medicalexpress.com](http://www.medicalexpress.com), June 1, 2016.
- Joszt, Laura, “Briefing shed light on the challenges and opportunities of HCV treatment.” *American Journal of Managed Care* (online newsletter), May 27, 2016.
- Plevin, Rebecca, “A financial cast for expanding access to costly hepatitis C drugs,” Southern California Public Radio (online blog), May 18, 2016.
- Feller, Stephen, “Study: Cheaper to cure hepatitis C sooner than later.” *United Press International* (online), May 9, 2016.
- Perrone, Matthew, “Breakthrough cholesterol drugs fizzle amid price pushback,” *Houston Chronicle* (online), April 22, 2016.
- Perrone, Matthew, “Why so few patients get the new cholesterol busters,” [www.cbsnews.com](http://www.cbsnews.com), April 20, 2016.
- *The Economist*, July 30, 2009. “Economics Focus: Waist Banned.” Discussion of Goldman, Dana, Darius N. Lakdawalla, and Yuhui Zheng, “Food Prices and the Dynamics of Body Weight.”
- Steenhuisen, Julie. “Drug Price Controls May Shorten Lives: Report.” *Reuters*, December 16, 2008. Discussion of Lakdawalla, Darius N., et al, “US Pharmaceutical Policy in a Global Marketplace.”
- *The Wall Street Journal*, August 25, 2006. “Econoblog: Cheap Food, Societal Norms and the Economics of Obesity.”
- Morin, Richard. “Breakthrough Breakdown.” *Washington Post*, July 11, 2004, page B5. Review of Goldman, Dana, Darius N. Lakdawalla, and Neeraj Sood, “HIV Breakthroughs and Risky Sexual Behavior.”
- Winslow, Ron. “Obesity Is Linked to Rising Disability in Younger Adults.” *Wall Street Journal*, January 9, 2004, page C1. Review of Lakdawalla, Darius N., Jay Bhattacharya, and Dana Goldman, “Are the Young Becoming More Disabled?”

- Akst, Daniel, *New York Times*, March 2, 2003. “Belt-Loosening in the Work Force.” Mention of Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
- Morin, Richard. “Age-Old Question.” *Washington Post*, January 31, 2003, page B5. Review of: Lakdawalla, Darius N., and Robert Schoeni, “The Decline in the Spousal Age Gap and the Demand for Long-Term Care.”
- Varian, Hal. “Economic Scene: Employment and Prosperity Affect Body Inflation.” *New York Times*, September 26, 2002, page C2. Review of Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
- Sydell, Laura. Radio Interview and Commentary. *Marketplace Morning Report*, National Public Radio. May 30, 2002. Review of: Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
- Edmonds, Sarah. Reuters News Service, May 29, 2002. “Innovation Behind Fatter Americans, Study Says.” Review of: Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
- Gongloff, Mark. CNN/Money Online, May 21, 2002. “Technology Makes You Fat.” Review of: Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
- Critser, Gregory, *Los Angeles Times*, April 28, 2002. “The Price of Pudge.” Mention of Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
- Koretz, Gene. “The Young and the Disabled.” *BusinessWeek*, June 4, 2001, page 30. Review of: Lakdawalla, Darius N., Jay Bhattacharya, and Dana Goldman, “Are the Young Becoming More Disabled?”
- Morin, Richard. “Unhealthy Paradox.” *Washington Post*, May 20, 2001, page B5. Review of: Lakdawalla, Darius N., Jay Bhattacharya, and Dana Goldman, “Are the Young Becoming More Disabled?”
- Postrel, Virginia. “American Waistlines Have Become the Victims of Economic Progress.” *The New York Times*, March 22, 2001, page C2. Review of: Lakdawalla, Darius N., and Tomas Philipson, “Technological Change and the Growth of Obesity.”
- *Investor’s Business Daily*, November 30, 1999. “Are Teachers Underpaid?” Review of: Lakdawalla, Darius N., “The Declining Relative Quality of Teachers.”
- Koretz, Gene. “The Coming Boom in Long-Term Care?” *BusinessWeek*, June 28, 1999, page 26. Review of: Lakdawalla, Darius N., and Tomas Philipson, “The Rise in Old-Age Longevity and the Market for Long-Term Care.”

#### **SELECTED PRESENTATIONS AND SPEAKING ENGAGEMENTS**

- Lakdawalla, Darius. “Keynote Address: On Drugs.” *Atlanta-Athens Health Economists Conference*. Atlanta, GA. September 12, 2025.
- Lakdawalla, Darius. “Drug Price Controls—What are the Unintended Consequences to Innovation?” *ISPOR Annual Meeting*. Montreal, Quebec, Canada. May 14, 2025.
- Lakdawalla, Darius. “How Should Health Economists and Health Policymakers Measure the Costs of Inequality?” *ISPOR Annual Meeting*. Montreal, Quebec, Canada. May 14, 2025.
- Lakdawalla, Darius. “Challenges in the Implementation of Generalized Cost-Effectiveness Analysis (GCEA): Debating a Path Forward.” *ISPOR Annual Meeting*. Montreal, Quebec, Canada. May 14, 2025.
- Lakdawalla, Darius. “Valuing Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model.” *ISPOR Short Course*. Montreal, Quebec, Canada. May 13, 2025.
- Lakdawalla, Darius. “Future-Proofing the Science of Cost-Effectiveness.” 2025 Western PharamcoEconomics Conference. University of Washington. Seattle, WA. April 1, 2025.
- Lakdawalla, Darius. Guest lecture at Carleton College Department of Economics. Northfield, MN. March 7, 2025.

- Lakdawalla, Darius. 2025 Global Payer Forum: Optimizing Patient Access Through Value-Based Healthcare. Virtual. February 20, 2025.
- Lakdawalla, Darius. “Origins and Implications of Health Technology Assessment.” Biotech CEO Forum. Virtual. December 2, 2024.
- Lakdawalla, Darius. “Value Assessment with Generalized Risk-Adjusted Cost-Effectiveness (GRACE).” Digital Healthcare for the Management of Functional Neurological Disorders. London, UK. November 26, 2024.
- Lakdawalla, Darius. “New Methods in Cost-Effectiveness.” Celebrating Cost-Effectiveness. Tufts University Center for the Evaluation of Value and Risk in Health. Cambridge, MA. October 26, 2024.
- Lakdawalla, Darius. “Benefits of Medicare Coverage for Weight-Loss Drugs.” 25th Annual Harvard Nutrition and Obesity Symposium. Virtual. June 5, 2024.
- Lakdawalla, Darius. “Soft Landing, Hard Problems.” Financial Times U.S. Pharma and Biotech Summit. New York, NY. May 16, 2024.
- Lakdawalla, Darius. “How Do We Add Flexibility and Patient-Centricity to Value?” BIO Value Assessment Summit. Washington, DC. May 15, 2024.
- Lakdawalla, Darius. “Economic Foundations of Distributional Cost-Effectiveness Analysis.” ISPOR Annual Meeting. Atlanta, GA. May 8, 2024.
- Lakdawalla, Darius. “The Case for Assessing Value with GRACE.” ISPOR Annual Meeting. Atlanta, GA. May 7, 2024.
- Lakdawalla, Darius. “Valuing Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model.” ISPOR Virtual Short Course. June 28-29, 2023.
- Lakdawalla, Darius. “Determining Value: A Biotech Industry Discussion on Value Assessments and Alternative Proposals.” BIO International Conference. Boston, MA. June 6, 2023.
- Lakdawalla, Darius. “Economic Impacts, Implications, and Approaches.” National Research Summit on Care, Services, and Supports for Persons with Dementia and their Care Partners. National Institute on Aging. March 22, 2023.
- Lakdawalla, Darius. “Inflation Reduction Act – Considering the Implications of Price Setting on Cost of Medicine.” Charles River Associates Chief Commercial Officer’s Forum at JP Morgan. January 10, 2023.
- Lakdawalla, Darius. “Dealing with Disability in Health Technology Assessment (HTA).” ISPOR Annual Meeting. May 16, 2022.
- Lakdawalla, Darius. “Rewarding Value in Global Pharmaceutical Markets.” Sustaining Global Pharmaceutical Innovation and Access. London Business School. April 20, 2022.
- Lakdawalla, Darius. “Frontiers in Value Assessment.” International Society for Pharmacoeconomics and Outcomes Research Annual Meeting, Plenary Session, May 20, 2020.
- Lakdawalla, Darius. “Economics of the Pharmaceutical Industry.” National Institutes of Health, Special Interest Group, March 5, 2020.
- Lakdawalla, Darius. “Mortality Risk, Insurance, and the Value of Life.” Wharton School of Business, November 1, 2019.
- Lakdawalla, Darius. “Mortality Risk, Insurance, and the Value of Life.” Questrom School of Business, Boston University, October 31, 2019.
- Lakdawalla, Darius. “Economics of the Pharmaceutical Industry.” Congressional Budget Office Panel of Health Advisors. September 20, 2019.
- Lakdawalla, Darius. “Novel elements of value in healthcare.” International Society for Pharmacoeconomics and Outcomes Research Annual Meeting, Issue Panel, May 20, 2019.
- Lakdawalla, Darius. “Value-based decision making in Healthcare.” UT-Southwestern Medical School, Guest Lecture to Faculty, February 7, 2019.
- Lakdawalla, Darius. “Food Purchasing Behaviors of New SNAP Recipients.” *Human Capital Economic Opportunity Working Group: Measuring and Improving Health Equity*, Los Angeles, CA, December 7, 2018.

- Lakdawalla, Darius. “On Drugs.” Toulouse School of Economics Guest Lecture, Toulouse, France, October 24, 2018
- Lakdawalla, Darius. “Patient Socioeconomic Status and Physician Supply Responses.” *Toulouse School of Economics Industrial/Organizational Seminar*, Toulouse, France, October 15, 2018
- Lakdawalla, Darius. “On Drugs.” *Canadian Health Economist Study Group*, McGill University, Montreal, Canada, May 31, 2018.
- Lakdawalla, Darius. “Should We Move Beyond Conventional Cost-Effectiveness Analysis.” *ISPOR Annual Meeting*, Baltimore, MD, May 21, 2018
- Lakdawalla, Darius. “ISPOR’s Special Task Force Report on US Value Assessment Frameworks: A Deeper Dive into Its Health Economic Underpinning.” *ISPOR Annual Meeting*, Boston, MA, May 22, 2017.
- Lakdawalla, Darius. “Actuarial and Health Economic Approaches to Assess Value: Speaking the Same Language or Need for Translation.” *ISPOR Annual Meeting*, Boston, MA, May 22, 2017.
- Lakdawalla, Darius. “A Roadmap to Consumer Clarity in Healthcare Decision Making.” *NPAF’s Spring Policy Consortium*, Washington, DC, May 17, 2017.
- Lakdawalla, Darius. “An Economic Perspective on Value Frameworks.” *AJMC’s ACO and Emerging Healthcare Delivery Coalition*, Scottsdale, AZ, May 5, 2017.
- Lakdawalla, Darius. “Risk Annuity and the Value of Life.” *HEC Montreal Seminar Series*, Montreal, Quebec, Canada, October 4, 2016.
- Lakdawalla, Darius. “Saving Lives or Saving Money? Understanding the Dual Nature of Physician Preferences.” *Johns Hopkins University Seminar Series*, Baltimore, MD, September 21, 2016.
- Lakdawalla, Darius. Health Economic Perspectives on Value Frameworks: “Measuring Value in Innovative Medicines.” *ASHEcon*, Philadelphia, PA, June 14, 2016.
- Lakdawalla, Darius. The Economics of Reimbursing New Medical Innovation: “An Economic Model of Surrogate Endpoints.” *ASHEcon*, Philadelphia, PA, June 13, 2016.
- Arnsten, Kathleen, Geoffrey Eich, Darius N. Lakdawalla, and Tomas Philipson. “The Future of Biosimilars: How Will Policy and Market Dynamics Impact Patient Value and Access in the U.S.?” *BIO International*, San Francisco, CA, June 8, 2016.
- Lakdawalla, Darius. “Budget Impact Analysis: An Acceptable Part of Value Assessments or a Discordant Concept?” *ISPOR Symposium*, Boston, MA, May 22, 2016.
- Lakdawalla, Darius. “The value of specialty drugs: Can we develop novel access policies for novel medicines?” *ISPOR Annual Meeting*, Boston, MA, May, 2016.
- Lakdawalla, Darius N., Anupam Jena, and Ryan Cleary. “Ending Hepatitis C: The Value of Curing the Nation’s Deadliest Blood-Borne Disease.” *National Viral Hepatitis Roundtable Meeting*, Washington, DC, May 2016.
- Goldman, Dana, Darius N. Lakdawalla, and Sam Nussbaum. “Research and Its Practical Application.” *Academy of Managed Care Pharmacy*, Panel R5, Impact of Value – Designing Innovative Models on Drug Costs, San Francisco, CA, April 2016.
- Lakdawalla. “The Cost and Value of Biomedical Innovation: Implications for Health Policy.” Presentation Title: “What Can We Learn from Recent Hepatitis C Treatments? Understanding the Pricing Process and Spending Consequences for Breakthrough Therapies.” Speaker, *Brookings Institute*, Washington, D.C., October, 2014.
- Lakdawalla. “Forecasting Population Health in Asia.” Keynote Speaker, *Japanese Health Economics Association*, Tokyo, Japan, September 2014.
- Lakdawalla. “Balancing the Value and Cost of Cancer Therapies.” Speaker, *BIO – 2014 International Convention*, San Diego, CA, June 2014.
- Lakdawalla. *ASHEcon – 5<sup>th</sup> Biennial Meeting*, June 2014.
- Lakdawalla. “Implications of the Affordable Care Act for Diabetes.” Presenter, *74<sup>th</sup> Scientific Sessions – ADA*, San Francisco, CA, June 2014.

- Lakdawalla. “The Affordable Care Act: Will It Help or Harm the Landscape for Biomedical Innovation and Technology?” Panelist, *ISPOR – 19<sup>th</sup> Annual International Meeting, Issue Panels – Session IV – Panel#2449*, Montreal, QC, Canada, June 2014.
- Lakdawalla. “The Insurance Value of Medical Innovation.” *National Bureau of Economic Research- Annual Conference-Health Economics Program Meeting*, Boston, MA, April 2014.
- Lakdawalla, “The Insurance Value of Medical Innovation.” Guest Lecturer, *School of Public Health, UCSB*, Santa Barbara, CA, March 2014 (Ted Frech)
- Lakdawalla. “The Insurance Value of Medical Innovation.” *National Bureau of Economic Research- Annual Conference-Healthcare Program Meeting*, Boston, MA, February 2014.
- Lakdawalla. “Research & Development, Manufacturing, and the Marketplace in California.” *California State Assembly Select Committee on Biotechnology - Information Hearing*, Sacramento, CA, February 2014.
- Lakdawalla, “The Effect of Medicare Part D on bargaining between Drug Companies and Insurance Companies.” Guest Lecturer, *School of Public Health, UCLA*, Los Angeles, CA, January 2014 (Bill Comanor)
- Lakdawalla. “Making the Case for Efforts in Personalized and Precision Health.” *World Economic Forum Annual Summit on the Global Agenda*, Abu Dhabi, UAE, November 2013.
- Lakdawalla. “Mental Health and Medicaid Policy.” *Women in Government Annual Healthcare Summit*, Washington, D.C., November 2013.
- Lakdawalla. “The Insurance value of Medical Technology.” *University of Illinois at Urbana-Champaign*, Champaign, IL, October 2013.
- Lakdawalla. *Council for Advancing Diabetes Care*, Santa Monica, CA, October 2013.
- Lakdawalla. “Innovation and Insurance.” *University of Chicago Applications Workshop*, Chicago, IL, September 2013.
- Lakdawalla. “Healthcare/Microeconomics Workshop.” *Indiana University*, Bloomington, IN, September 2013.
- Lakdawalla. “Best of Both Worlds: Uniting Universal Coverage and Personal Choice in Health Care.” *American Enterprise Institute Launch Event*, Washington, D.C., August 2013.
- Lakdawalla. “Value of Adherence.”/ Session 3: How do we unlock the value of better patient adherence? *AJMC Patient-Centered Diabetes Care Symposium*, Chicago, IL, June 2013.
- Lakdawalla. Panel Discussion of “How Do We Balance Patient Value & Payer Cost in Oncology?” *International Society for Pharmacoeconomics and Outcomes Research 18<sup>th</sup> Annual International Meeting*, New Orleans, LA, May 2013.
- Lakdawalla. *Council for Advancing Diabetes Care*, Arlington, VA, May 2013.
- Lakdawalla. Discussion of “Hospital Market Structure, Pricing and Quality of Care.” *Allied Social Sciences Association Annual Meeting*, San Diego, CA, January 2013.
- Lakdawalla. “Does Statin Use Adversely Affect Health Behaviors?” *Allied Social Sciences Association Annual Meeting*, San Diego, CA, January 2013.
- Lakdawalla. “Medicare Part D and Negotiating Leverage in the Pharmaceutical Industry.” *University of Chicago Applications of Economics Workshop*, Chicago, IL, May 2010.
- Lakdawalla. Discussion of “The Rise of Paragraph IV Challenges on Startup Alliance Formation in the Pharmaceutical Industry.” *Southern California Applied Microeconomics Conference*, Claremont, CA, April 2010.
- Lakdawalla. “Medicare Part D and Pharmaceutical Advertising.” *Robert Wood Johnson Fellowship External Speaker Series*, Berkeley, CA, March 2010.
- Lakdawalla. “Tort Liability for Prescription Drugs.” *National Bureau of Economic Research Health Care Program Meeting*, Cambridge, MA, March 2010.
- Lakdawalla. “Medicare Part D and Pharmaceutical Advertising.” *American Economic Association Annual Meetings*, Atlanta, GA, January 2010.
- Lakdawalla, “Health Insurance as a Two-Part Pricing Contract.” *Toulouse School of Economics Health Economics Conference*, Toulouse, France, October 2009.

- Lakdawalla, “US Pharmaceutical Policy in a Global Context.” *Eugene Garfield Award Presentation Lunch*, Washington, D.C., October 2009.
- Lakdawalla. “Health Insurance as a Two-Part Pricing Contract.” *Brown University Department of Economics Seminar Series*, Providence, RI, September 2009.

#### **PHD ADVISEES**

- Committee Chair for Drishti Baid, Current
- Committee Chair for Ian Davis, Current
- Committee Chair for Rahul Mudumba, Current
- Primary Advisor for Azka Imran, Current
- Committee Member for Shihan Jin, Current
- Committee Member for Shengjia Xu, Graduated 2023 (June)
- Outside Reviewer for Gosia Majewski (Toulouse School of Economics), Graduated 2023 (June)
- Committee Member for Yifan Wei, Graduated 2023 (December)
- Committee Member for Phyllis Barkman Ferrell (Indiana University), Graduated 2023 (November)
- Committee Member for Sam Crawford, Graduated 2022 (August)
- Committee Chair for Jaehong Kim, Graduated 2021 (August)
- Proposal Committee Member for Jeffrey Yu, Graduated 2021 (August)
- Proposal Committee Member for Jianhui Xu, Graduated 2021 (August)
- Committee Chair for Jonathan Salcedo, Graduated 2020
- Committee Chair for Laura Henkhaus, Graduated 2019
- Committee Member for Eunhae Shin, Graduated 2019
- Committee Member for Xiaohan Hu, Graduated 2019
- Committee Member for Sarah Axeen, Graduated 2016